Introduction {#s1}
============

Protein aggregation and aberrant phase transitions are elicited by a variety of cellular stressors and can be highly toxic ([@bib15]; [@bib28]; [@bib44]). To counter this challenge, cells have evolved specialized protein disaggregases to reverse aggregation and restore resolubilized proteins to native structure and function ([@bib110]; [@bib113]). Indeed, protein disaggregases are conserved across all domains of life, with orthologues of Hsp104, a ring-shaped hexameric AAA+ protein, powering protein disaggregation and reactivation (as opposed to degradation) in eubacteria and nonmetazoan eukaryotes ([@bib40]; [@bib41]; [@bib95]; [@bib108]). In nonmetazoan eukaryotes, Hsp104 functions in the cytoplasm and nucleus ([@bib86]; [@bib124]; [@bib131]), whereas the closely-related AAA+ disaggregase, Hsp78, resolubilizes and reactivates proteins in mitochondria ([@bib58]; [@bib104]). Curiously, at the evolutionary transition from protozoa to metazoa both Hsp104 and Hsp78 are lost and are subsequently absent from all animal species ([@bib30]). This loss of Hsp104 and Hsp78 is perplexing given that toxic protein aggregation remains a major challenge in metazoa ([@bib28]). Indeed, it is even more baffling since ectopic expression of Hsp104 is well tolerated by animal cells and can be neuroprotective in animal models of neurodegenerative disease ([@bib22]; [@bib23]; [@bib50]; [@bib62]; [@bib91]; [@bib100]; [@bib128]; [@bib138]).

Metazoa may partially compensate for the absence of Hsp104 activity in the cytoplasm and nucleus with alternative general protein-disaggregase systems, such as Hsp110, Hsp70, Hsp40, and small heat-shock proteins ([@bib27]; [@bib71]; [@bib84]; [@bib106]; [@bib109]; [@bib110]; [@bib126]) as well as client-specific disaggregases in the cytoplasm such as nuclear-import receptors ([@bib44]; [@bib43]; [@bib83]; [@bib140]). However, Hsp110 is not found in mitochondria ([@bib130]). Thus, it continues to remain uncertain whether, in the absence of Hsp78, metazoan mitochondria harbor a disaggregase that solubilizes and reactivates aggregated proteins.

Here, we investigate whether Skd3 (encoded by human *CLPB*) might act as a mitochondrial protein disaggregase in metazoa ([Figure 1a](#fig1){ref-type="fig"}). Skd3 is a ubiquitously expressed, mitochondrial AAA+ protein of poorly-defined function, which is related to Hsp104 and Hsp78 via its HCLR clade AAA+ domain ([Figure 1a](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}; [@bib31]; [@bib89]; [@bib107]). Skd3 appears to play an important role in maintaining mitochondrial structure and function ([@bib14]). Curiously, Skd3 first appears in evolution alongside Hsp104 and Hsp78 in choanoflagellates, a group of free-living unicellular and colonial flagellate eukaryotes that are the closest extant protozoan relatives of animals ([Figure 1b](#fig1){ref-type="fig"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"}; [@bib8]; [@bib30]). During the complex evolutionary transition from protozoa to metazoa, Skd3 is retained, whereas Hsp104 and Hsp78 are lost ([@bib30]). Indeed, Skd3 is conserved in many metazoan lineages ([Figure 1a,b](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, and [Supplementary file 1](#supp1){ref-type="supplementary-material"}; [@bib30]).

![Skd3 is homologous to Hsp104 and Hsp78 and is conserved across diverse metazoan lineages.\
(**A**) Domain map depicting *S. cerevisiae* Hsp104, *S. cerevisiae* Hsp78, and *H. sapiens* Skd3. Hsp104 is composed of a N-terminal domain (NTD), nucleotide-binding domain 1 (NBD1), middle domain (MD), nucleotide-binding domain 2 (NBD2), and C-terminal domain (CTD). Hsp78 is composed of a mitochondrial-targeting signal (MTS), NBD1, MD, NBD2, and CTD. Skd3 is composed of a MTS, a short hydrophobic stretch of unknown function, an ankyrin-repeat domain (ANK) containing four ankyrin repeats, an NBD that is homologous to Hsp104 and Hsp78 NBD2, and a CTD. (**B**) Phylogenetic tree depicting a Clustal Omega alignment of Skd3 sequences from divergent metazoan lineages and the protozoan *Monosiga brevicollis*. The alignment shows conservation of Skd3 across diverse species and shows high similarity between mammalian Skd3 proteins.](elife-55279-fig1){#fig1}

Skd3 is comprised of a mitochondrial-targeting signal (MTS), followed by a short hydrophobic stretch, an ankyrin-repeat domain (ANK), an AAA+ nucleotide-binding domain (NBD), and a small C-terminal domain (CTD) ([Figure 1a](#fig1){ref-type="fig"}). The Skd3 NBD closely resembles NBD2 of Hsp104 and Hsp78 ([Figure 1a](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Aside from this similarity, Skd3 is highly divergent from Hsp104 and Hsp78 ([Figure 1a](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}; [@bib126]). For example, Skd3, Hsp104, and Hsp78 all have short CTDs, but these are divergent with the Skd3 CTD being basic compared to the more acidic Hsp104 and Hsp78 CTDs ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Moreover, the other domains in Hsp104 (N-terminal domain \[NTD\], NBD1, and middle domain \[MD\]) and Hsp78 (NBD1 and MD) are not found in Skd3 ([Figure 1a](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). In their place, is an ankyrin-repeat domain ([Figure 1a](#fig1){ref-type="fig"}), which interestingly is an important substrate-binding domain of another protein disaggregase, chloroplast signal recognition particle 43 (cpSRP43) ([@bib54]; [@bib53]; [@bib72]; [@bib82]).

Importantly, mutations in the Skd3 ankyrin-repeat domain and NBD are linked to the rare, but severe mitochondrial disorder, 3-methylglutaconic aciduria, type VII (MGCA7) ([@bib9]; [@bib55]; [@bib56]; [@bib94]; [@bib101]; [@bib135]; [@bib134]). MGCA7 is an autosomal recessive metabolic disorder that presents with increased levels of 3-methylglutaconic acid (3-MGA), neurologic deterioration, and neutropenia ([@bib135]). Typically, patients present with infantile onset of a progressive encephalopathy with movement abnormalities and delayed psychomotor development ([@bib135]). Other common, but variable, phenotypes include cataracts, seizures, and recurrent infections ([@bib135]). These issues can be severe with afflicted infants typically only living for a few weeks or months ([@bib135]). Patients may also present with more moderate phenotypes, including neutropenia, hypotonia, spasticity, movement abnormalities, epilepsy, and intellectual disability ([@bib135]). Mildly affected individuals have no neurological problems, normal life expectancy, but present with neutropenia ([@bib135]). There is no cure and no effective therapeutics for severe or moderate forms of MGCA7. Moreover, little is known about how Skd3 mutations might cause disease.

Collectively, these various observations concerning Skd3 led us to hypothesize that Skd3 is a metazoan mitochondrial protein disaggregase of key importance for mitochondrial proteostasis. We further hypothesized that MGCA7-associated Skd3 mutations would disrupt disaggregase activity. Our investigation of these hypotheses is detailed below. Briefly, we find that Skd3 is an ATP-dependent mitochondrial protein disaggregase that is activated by the rhomboid protease, PARL, and inactivated by MGCA7-linked mutations.

Results {#s2}
=======

Skd3 couples ATP hydrolysis to protein disaggregation and reactivation {#s2-1}
----------------------------------------------------------------------

To biochemically dissect the activity of Skd3, we purified full-length Skd3 (see Materials and methods), lacking the mitochondrial targeting signal, which is cleaved by the mitochondrial-processing peptidase (MPP) upon import into mitochondria ([Figure 2a](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1a--d](#fig2s1){ref-type="fig"}; [@bib17]; [@bib134]). We term this form of Skd3, ~MPP~Skd3. We first assessed that ATPase activity of ~MPP~Skd3 and found that it is active ([Figure 2b](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2a](#fig2s2){ref-type="fig"}). Indeed, ~MPP~Skd3 displayed robust ATPase activity that was comparable to Hsp104 and over two-fold higher than previously reported values for ~MPP~Skd3 activity ([Figure 2b](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2a](#fig2s2){ref-type="fig"}; [@bib81]; [@bib134]).

![Skd3 is a protein disaggregase.\
(**A**) Domain map depicting the Mitochondrial-processing peptidase (MPP) cleavage site and mature-length Skd3 (~MPP~Skd3). The MTS was predicted using MitoProt in agreement with previous work, as outlined in the Materials and methods. The positions of the Walker A mutation (K387A) predicted to disrupt ATP binding and hydrolysis, pore-loop tyrosine mutation (Y430A) predicted to disrupt substrate binding, and Walker B mutation (E455Q) predicted to disrupt ATP hydrolysis are shown. (**B**) ~MPP~Skd3 is an ATPase. ATPase assay comparing ~MPP~Skd3 and Hsp104. ~MPP~Skd3 and Hsp104 ATPase were compared to buffer using one-way ANOVA and a Dunnett's multiple comparisons test (N = 4, individual data points shown as dots, bars show mean ± SEM, \*\*\*\*p\<0.0001). (**C**) Luciferase disaggregation/reactivation assay showing that ~MPP~Skd3 has disaggregase activity in the presence but not absence of ATP. Luciferase activity was buffer subtracted and normalized to Hsp104 + Hsp70/Hsp40. Luciferase activity was compared to buffer using one-way ANOVA and a Dunnett's multiple comparisons test (N = 4, individual data points shown as dots, bars show mean ± SEM, \*\*\*\*p\<0.0001). (**D**) ATPase assay comparing ~MPP~Skd3, ~MPP~Skd3^K387A^ (Walker A mutant), ~MPP~Skd3^E455Q^ (Walker B mutant), and ~MPP~Skd3^Y430A^ (Pore-Loop mutant), showing that both Walker A and Walker B mutations abolish Skd3 ATPase activity, whereas the Pore Loop mutation reduces ATPase activity. ATPase activity was compared to buffer using one-way ANOVA and a Dunnett's multiple comparisons test (N = 4, individual data points shown as dots, bars show mean ± SEM, \*p\<0.05, \*\*\*\*p\<0.0001). (**E**) Luciferase disaggregation/reactivation assay comparing ~MPP~Skd3 to Walker A, Walker B, and Pore-Loop variants demonstrating that ATP binding, ATP hydrolysis, and pore-loop contacts are essential for Skd3 disaggregase activity. Luciferase activity was buffer subtracted and normalized to Hsp104 + Hsp70/Hsp40. Luciferase activity was compared to buffer using one-way ANOVA and a Dunnett's multiple comparisons test (N = 4, individual data points shown as dots, bars show mean ± SEM, \*\*\*\*p\<0.0001).](elife-55279-fig2){#fig2}

To determine if ~MPP~Skd3 is a disaggregase we used a classic aggregated substrate, urea-denatured firefly luciferase aggregates, which form aggregated structures of ∼500--2000 kDa and greater in size that are devoid of luciferase activity ([@bib24]; [@bib40]). Indeed, very few luciferase species smaller than \~400 kDa can be detected ([@bib40]). Importantly, these samples are devoid of misfolded, monomeric luciferase ([@bib40]). Reactivation of luciferase in this assay is thus primarily achieved by the extraction and subsequent refolding of monomeric luciferase (M~w~ \~61 kDa) from large aggregated structures (∼500--2,000 kDa or larger) ([@bib40]). Hence, in this assay, luciferase reactivation is an accurate proxy for luciferase disaggregation. Importantly, Hsp70 and Hsp40 are unable to disaggregate and reactivate luciferase found in these large aggregated structures (∼500--2,000 kDa or larger) ([@bib40]). Indeed, Hsp70 and Hsp40 were unable to recover any active luciferase (\~0.05 ± 0.00% \[mean ± SEM\] native luciferase activity) and were similar to the buffer control (\~0.04 ± 0.00% native luciferase activity) ([Figure 2c](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2b,d](#fig2s2){ref-type="fig"}). As expected, Hsp104 alone was also unable to disaggregate and reactivate luciferase (\~0.08 ± 0.01% native luciferase activity) ([Figure 2c](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2b,d](#fig2s2){ref-type="fig"}; [@bib24]; [@bib40]). By contrast, the combination of Hsp104, Hsp70, and Hsp40 recovered \~7.68 ± 0.44% native luciferase activity ([Figure 2c](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2b,d](#fig2s2){ref-type="fig"}; [@bib40]). Remarkably, ~MPP~Skd3 displayed robust disaggregase activity in the presence of ATP as it was able to recover \~2.87 ± 0.17% native luciferase activity ([Figure 2c](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2b,c](#fig2s2){ref-type="fig"}). Indeed, ~MPP~Skd3 displayed \~40% of the disaggregase activity of Hsp104 plus Hsp70 and Hsp40 under these conditions ([Figure 2c](#fig2){ref-type="fig"}). While Hsp104 required the presence of Hsp70 and Hsp40 to disaggregate luciferase ([Figure 2c](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2b,c](#fig2s2){ref-type="fig"}; [@bib24]; [@bib40]), ~MPP~Skd3 had no requirement for Hsp70 and Hsp40 ([Figure 2c](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2b,c](#fig2s2){ref-type="fig"}). This finding indicates that ~MPP~Skd3 is a 'stand-alone' disaggregase.

Next, we assessed the nucleotide requirements for ~MPP~Skd3 disaggregase activity. ~MPP~Skd3 disaggregase activity was supported by ATP but not by the absence of nucleotide or the presence of ADP ([Figure 2c](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2b,d](#fig2s2){ref-type="fig"}). Likewise, neither the non-hydrolyzable ATP analogue, AMP-PNP, nor the slowly hydrolyzable ATP analogue, ATPγS, could support ~MPP~Skd3 disaggregase activity ([Figure 2---figure supplement 2b,d](#fig2s2){ref-type="fig"}). Collectively, these data suggest that ~MPP~Skd3 disaggregase activity requires multiple rounds of rapid ATP binding and hydrolysis, which is similar mechanistically to Hsp104 ([@bib24]; [@bib111]; [@bib112]).

We next investigated the role of conserved AAA+ elements in Skd3 activity. Thus, we mutated: (1) a critical lysine in the Walker A motif to alanine (K387A), which is predicted to disrupt ATP binding and hydrolysis ([@bib45]; [@bib107]); (2) a critical glutamate in the Walker B motif to glutamine (E455Q), which is predicted to disrupt ATP hydrolysis but not ATP binding ([@bib45]; [@bib107]); and (3) a highly-conserved tyrosine in the predicted -GYVG- substrate-binding loop to alanine that is predicted to disrupt substrate binding (Y430A) as in related HCLR clade AAA+ ATPases ([@bib35]; [@bib45]; [@bib63]; [@bib70]; [@bib97]; [@bib107]). The equivalent Walker A, Walker B, and substrate-binding loop mutations in NBD1 and NBD2 of Hsp104 severely disrupt disaggregase activity ([@bib24]; [@bib65]; [@bib125]). Likewise, ~MPP~Skd3^K387A^ (Walker A mutant) and ~MPP~Skd3^E455Q^ (Walker B mutant) displayed greatly reduced ATPase and disaggregase activity ([Figure 2d,e](#fig2){ref-type="fig"}). Thus, ~MPP~Skd3 couples ATP binding and hydrolysis to protein disaggregation.

Interestingly, the pore-loop variant, ~MPP~Skd3^Y430A^, exhibited reduced ATPase activity compared to ~MPP~Skd3, but much higher ATPase activity than ~MPP~Skd3^K387A^ and ~MPP~Skd3^E455Q^ ([Figure 2d](#fig2){ref-type="fig"}). This reduction in ATPase activity was unexpected as equivalent mutations in Hsp104 do not affect ATPase activity ([@bib24]; [@bib66]; [@bib65]; [@bib125]). ~MPP~Skd3^Y430A^ was also devoid of disaggregase activity ([Figure 2e](#fig2){ref-type="fig"}). The inhibition of disaggregase activity by Y430A was much more severe than the inhibition of ATPase activity ([Figure 2d,e](#fig2){ref-type="fig"}), which suggests that the pore-loop Y430 might make direct contact with substrate to drive protein disaggregation as in Hsp104 ([@bib24]; [@bib35]). Thus, the conserved putative substrate-binding tyrosine of the -GYVG- pore-loop is critical for ~MPP~Skd3 disaggregase activity.

Skd3 disaggregase activity is enhanced by PARL cleavage {#s2-2}
-------------------------------------------------------

We noticed that Skd3 contains an undefined, 35-amino acid, hydrophobic stretch between the N-terminal MTS and the ankyrin-repeat domain ([Figure 1a](#fig1){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Intriguingly, Skd3 is cleaved by the inner-membrane rhomboid protease, PARL, at amino acid 127, between the 35-amino acid, hydrophobic stretch and the ankyrin-repeat domain ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}; [@bib99]; [@bib117]). Sequence analysis shows that the 35-amino acid, hydrophobic stretch and the PARL-cleavage motif are both highly conserved among mammalian Skd3 orthologues ([Figure 3---figure supplement 2a](#fig3s2){ref-type="fig"}). Thus, we hypothesized that this 35-amino acid, hydrophobic stretch might be auto-inhibitory for Skd3 activity.

To determine whether PARL cleavage of this 35-amino acid, hydrophobic stretch regulates Skd3 activity, we purified Skd3 without this region (~PARL~Skd3) ([Figure 3a](#fig3){ref-type="fig"}). We found that the absence of the 35-residue stretch that is removed by PARL slightly decreased Skd3 ATPase activity compared to ~MPP~Skd3 ([Figure 3b](#fig3){ref-type="fig"} and [Figure 3---figure supplement 2b](#fig3s2){ref-type="fig"}). Moreover, we find that ~MPP~Skd3 ATPase activity is not stimulated by the model substrate, casein, a classic peptide-stimulator of Hsp104 ATPase activity ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}; [@bib10]; [@bib35]). By contrast, ~PARL~Skd3 ATPase activity is mildly stimulated by casein ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). This finding indicates that ~PARL~Skd3 may interact more effectively with substrates than ~MPP~Skd3 due to the removal of the 35-amino acid, hydrophobic stretch.

![PARL cleavage enhances Skd3 disaggregase activity.\
(**A**) Domain map depicting ~MPP~Skd3 and the PARL cleavage site and corresponding PARL-cleaved Skd3 (~PARL~Skd3). The positions of the Walker A mutation (K387A) predicted to disrupt ATP binding and hydrolysis, pore-loop tyrosine mutation (Y430A) predicted to disrupt substrate binding, and Walker B mutation (E455Q) predicted to disrupt ATP hydrolysis are shown. (**B**) ATPase assay comparing ~MPP~Skd3 and ~PARL~Skd3. ~PARL~Skd3 is catalytically active, but is slightly less active than ~MPP~Skd3. ~PARL~Skd3 and Hsp104 ATPase were compared to ~MPP~Skd3 ATPase using one-way ANOVA and a Dunnett's multiple comparisons test (N = 6, individual data points shown as dots, bars show mean ± SEM, \*p\<0.05, \*\*\*\*p\<0.0001). (**C**) Luciferase disaggregation/reactivation assay comparing ~MPP~Skd3 disaggregase activity to ~PARL~Skd3. ~PARL~Skd3 was over 10-fold more active than ~MPP~Skd3. Luciferase activity was buffer subtracted and normalized to Hsp104 + Hsp70/Hsp40. Luciferase activity was compared to ~MPP~Skd3 using one-way ANOVA and a Dunnett's multiple comparisons test (N = 6, individual data points shown as dots, bars show mean ± SEM, \*\*\*\*p\<0.0001). (**D**) ATPase assay comparing ~PARL~Skd3, ~PARL~Skd3^K387A^ (Walker A), ~PARL~Skd3^E455Q^ (Walker B), and ~PARL~Skd3^Y430A^ (Pore Loop), showing that both Walker A and Walker B mutations abolish Skd3 ATPase activity, whereas the Pore-Loop mutation reduces ATPase activity. ATPase activity was compared to buffer using one-way ANOVA and a Dunnett's multiple comparisons test (N = 4, individual data points shown as dots, bars show mean ± SEM, \*\*\*\*p\<0.0001). (**E**) Luciferase disaggregation/reactivation assay comparing ~PARL~Skd3 to Walker A, Walker B, and Pore-Loop variants showing that ATP binding, ATP hydrolysis, and pore-loop contacts are essential for ~PARL~Skd3 disaggregase activity. Luciferase activity was buffer subtracted and normalized to Hsp104 + Hsp70/Hsp40. Luciferase activity was compared to buffer using one-way ANOVA and a Dunnett's multiple comparisons test (N = 4, individual data points shown as dots, bars show mean ± SEM, \*\*\*\*p\<0.0001).](elife-55279-fig3){#fig3}

Remarkably, the absence of the N-terminal peptide known to be removed by PARL unleashed Skd3 disaggregase activity ([Figure 3c](#fig3){ref-type="fig"} and [Figure 3---figure supplement 2c,d](#fig3s2){ref-type="fig"}). Indeed, ~PARL~Skd3 exhibited over 10-fold higher disaggregase activity (\~44.06 ± 3.78% native luciferase activity recovered, mean ± SEM) compared to ~MPP~Skd3 (\~3.10 ± 0.44% native luciferase activity recovered) and over five-fold higher disaggregation activity than Hsp104 plus Hsp70 and Hsp40 (\~8.58 ± 1.20% native luciferase activity recovered), despite ~PARL~Skd3 having lower ATPase activity when compared to ~MPP~Skd3 ([Figure 3b,c](#fig3){ref-type="fig"}, and [Figure 3---figure supplement 2b,c,d](#fig3s2){ref-type="fig"}). These results suggest that Skd3 disaggregase activity is likely regulated by PARL and that PARL-activated Skd3 is a powerful, stand-alone protein disaggregase with activity comparable to potentiated Hsp104 variants ([@bib50]; [@bib52]; [@bib51]; [@bib122]; [@bib121]; [@bib125]).

As with ~MPP~Skd3, we found that ~PARL~Skd3 disaggregase activity was supported by ATP, but not in the absence of nucleotide or in the presence of ADP, non-hydrolyzable AMP-PNP, or slowly hydrolyzable ATPγS ([Figure 3c](#fig3){ref-type="fig"} and [Figure 3---figure supplement 2e](#fig3s2){ref-type="fig"}). Likewise, ~PARL~Skd3^K387A^ (Walker A mutant) and ~PARL~Skd3^E455Q^ (Walker B mutant) lacked ATPase and disaggregase activity ([Figure 3d,e](#fig3){ref-type="fig"}), indicating that ~PARL~Skd3 couples ATP binding and hydrolysis to protein disaggregation. Curiously, ~PARL~Skd3^Y430A^ (pore-loop mutant) exhibited a larger reduction in ATPase activity than ~MPP~Skd3^Y430A^ ([Figures 2d](#fig2){ref-type="fig"} and [3d](#fig3){ref-type="fig"}), indicating that the conserved tyrosine in the conserved putative substrate-binding -GYVG- pore loop impacts ATPase activity in Skd3, whereas it has no effect in Hsp104 ([@bib24]; [@bib125]). ~PARL~Skd3^Y430A^ was devoid of disaggregase activity ([Figure 3e](#fig3){ref-type="fig"}), which could be due to reduced ATPase activity, reduced substrate binding, or both.

PARL-activated Skd3 solubilizes α-synuclein fibrils {#s2-3}
---------------------------------------------------

Next, we assessed whether ~PARL~Skd3 could disassemble a stable amyloid substrate, which makes more stringent demands on a disaggregase ([@bib24]). Thus, we turned to α-synuclein fibrils, which are connected to Parkinson's disease and various synucleinopathies ([@bib47]; [@bib115]; [@bib116]). We utilized a strain of synthetic α-synuclein fibrils capable of eliciting Parkinson's disease-like symptoms in mice ([@bib64]). We employed samples of preformed α-synuclein fibrils that had completely assembled (i.e. 100% of α-synuclein was in the assembled fibril state) and were devoid of soluble α-synuclein ([Figure 4a,b](#fig4){ref-type="fig"}). Using a sedimentation assay combined with a dot-blot, we found that ~PARL~Skd3, but not ~MPP~Skd3 (data not shown), disaggregated these disease-causing fibrils in the presence, but not absence of ATP ([Figure 4a,b](#fig4){ref-type="fig"}). Thus, ~PARL~Skd3 is a powerful protein disaggregase, which could have applications as a potential therapeutic agent to eliminate disease-causing α-synuclein fibrils that underlie Parkinson's disease and other synucleinopathies.

![Skd3 disaggregates α-synuclein fibrils.\
(**A**) Representative dot blot of α-synuclein disaggregation assay. Blot shows solubilization of α-synuclein fibrils by ~PARL~Skd3 in the presence of an ATP regeneration system (ARS), but not in the presence of ~PARL~Skd3 or ARS alone. (N = 3). (**B**) Quantification of α-synuclein disaggregation assay showing that ~PARL~Skd3 in the presence of an ARS disaggregates α-synuclein fibrils. Results are normalized as fraction in the supernatant relative to the fraction in the supernatant and the pellet. The fraction of α-synuclein in the supernatant was compared to buffer using a repeated measure one-way ANOVA and a Dunnett's multiple comparisons test (N = 3, individual data points shown as dots, bars show mean ± SEM, \*p\<0.05).](elife-55279-fig4){#fig4}

Skd3 disaggregase activity requires the ankyrin-repeat domain and NBD {#s2-4}
---------------------------------------------------------------------

To further investigate the mechanism of Skd3 disaggregase activity, we purified the isolated ankyrin-repeat domain and NBD as separate proteins ([Figure 5a](#fig5){ref-type="fig"}). Neither the isolated ankyrin-repeat domain nor the isolated NBD exhibited ATPase activity or disaggregase activity ([Figure 5b,c](#fig5){ref-type="fig"}). The lack of ATPase activity and disaggregase activity of the isolated NBD is consistent with a similar lack of activity of isolated NBD2 from Hsp104 or bacterial ClpB and is likely attributed to a lack of hexamer formation, as is observed for ClpB NBD2 ([@bib6]; [@bib46]; [@bib79]). Thus, the ankyrin-repeat domain and NBD combine in *cis* to enable Skd3 ATPase activity and disaggregase activity. We also tested whether the two domains could combine in *trans* as two separate proteins to yield an active ATPase or disaggregase. However, we found that equimolar amounts of the ankyrin-repeat domain and NBD were also inactive ([Figure 5b,c](#fig5){ref-type="fig"}). Thus, Skd3 is unlike bacterial ClpB, which can be reconstituted in *trans* by separate NTD-NBD1-MD and NBD2 proteins ([@bib6]). These findings suggest that the covalent linkage of the ankyrin-repeat domain and NBD is critical for forming a functional ATPase and disaggregase. Importantly, they also predict that truncated MGCA7-linked Skd3 variants, such as R250\* and K321\* (where \* indicates a stop codon), which lack the NBD would be inactive for protein disaggregation and indeed any ATPase-dependent activities.

![The ankyrin-repeat domain and NBD are required for Skd3 disaggregase activity.\
(**A**) Domain maps showing the Skd3~ANK~ and Skd3~NBD~ constructs. (**B**) ATPase assay comparing Skd3~ANK~ and Skd3~NBD~ ATPase activity. Results show that Skd3~ANK~, Skd3~NBD~, and Skd3~ANK~ + Skd3~NBD~ do not have ATPase activity. Data are from the same experiments as [Figure 3B](#fig3){ref-type="fig"}. ATPase activity was compared to buffer using one-way ANOVA and a Dunnett's multiple comparisons test (N = 4, individual data points shown as dots, bars show mean ± SEM, \*\*\*\*p\<0.0001). (**C**) Luciferase disaggregation/reactivation assay comparing Skd3~ANK~, Skd3~NBD~, and Skd3~ANK~ + Skd3~NBD~ d activity. Results show that Skd3~ANK~, Skd3~NBD~, or Skd3~ANK~ + Skd3~NBD~ are inactive disaggregases. Data are from same experiments as [Figure 3C](#fig3){ref-type="fig"}. Luciferase activity was buffer subtracted and normalized to Hsp104 plus Hsp70 and Hsp40. Luciferase disaggregase activity was compared to buffer using one-way ANOVA and a Dunnett's multiple comparisons test (N = 4, individual data points shown as dots, bars show mean ± SEM, \*\*\*\*p\<0.0001).](elife-55279-fig5){#fig5}

Skd3 disaggregase activity is not stimulated by Hsp70 and Hsp40 {#s2-5}
---------------------------------------------------------------

Hsp104 and Hsp78 collaborate with Hsp70 and Hsp40 to disaggregate many substrates ([Figures 2c,e](#fig2){ref-type="fig"} and [3c,e](#fig3){ref-type="fig"}; [@bib24]; [@bib40]; [@bib58]). By contrast, Skd3 does not require Hsp70 and Hsp40 for protein disaggregation ([Figures 2c,e](#fig2){ref-type="fig"}, [3c,e](#fig3){ref-type="fig"} and [4a,b](#fig4){ref-type="fig"}). This finding is consistent with Skd3 lacking the NTD, NBD1, and MD of Hsp104, which interact with Hsp70 ([@bib25]; [@bib60]; [@bib118]; [@bib119]). Nonetheless, Hsp70 and Hsp40 might still augment Skd3 disaggregase activity. Thus, we tested if Hsp70 and Hsp40 could stimulate Skd3 disaggregase activity. However, neither ~MPP~Skd3 nor ~PARL~Skd3disaggregase activity was stimulated by Hsp70 and Hsp40 ([Figure 6a,b](#fig6){ref-type="fig"}). Thus, Skd3 is a stand-alone disaggregase that works independently of the Hsp70 chaperone system.

![Skd3 does not collaborate with Hsp70 and Hsp40 in protein disaggregation.\
(**A**) Luciferase disaggregation/reactivation comparing ~MPP~Skd3 disaggregase activity in the presence or absence of Hsp70 (Hsc70) and Hsp40 (Hdj1). Luciferase activity was buffer subtracted and normalized to Hsp104 plus Hsp70 and Hsp40. Results show a stimulation of Hsp104 disaggregase activity by Hsp70 and Hsp40, but no stimulation of disaggregase activity for ~MPP~Skd3. ~MPP~Skd3 plus Hsp70 and Hsp40 was compared to ~MPP~Skd3 using a two-tailed, unpaired t-test. Test found no significant difference in disaggregation activity. (N = 4, individual data points shown as dots, bars show mean ± SEM). (**B**) Luciferase disaggregation/reactivation comparing ~PARL~Skd3 disaggregase activity in the presence or absence of Hsp70 and Hsp40. Luciferase activity was buffer subtracted and normalized to Hsp104 plus Hsp70 and Hsp40. Results show no stimulation of disaggregase activity for ~PARL~Skd3 by Hsp70 and Hsp40. ~PARL~Skd3 plus Hsp70 and Hsp40 was compared to ~PARL~Skd3 using a two-tailed, unpaired t-test. Test found no significant difference in disaggregation activity. (N = 4, individual data points shown as dots, bars show mean ± SEM).](elife-55279-fig6){#fig6}

Human cells lacking Skd3 exhibit reduced solubility of mitochondrial proteins {#s2-6}
-----------------------------------------------------------------------------

Given the potent disaggregase activity of Skd3, we predicted that deletion of Skd3 in human cells would result in decreased protein solubility in mitochondria. To determine the effect of Skd3 on protein solubility in mitochondria, we compared the relative solubility of the mitochondrial proteome in wild-type and Skd3 knockout human HAP1 cells ([Figure 7---figure supplement 1a--c](#fig7s1){ref-type="fig"}) using mass spectrometry as described in [Figure 7a](#fig7){ref-type="fig"}. Overall, we observed decreased protein solubility in mitochondria from the Skd3 knockout cells when compared to their wild-type counterparts ([Figure 7b](#fig7){ref-type="fig"} and [Figure 7---figure supplement 2a](#fig7s2){ref-type="fig"}). Using Gene Ontology (GO) analysis for cellular component, we found that proteins in the inner mitochondrial membrane and intermembrane space were enriched in the insoluble fraction in the absence of Skd3 ([Figure 7---figure supplement 2a](#fig7s2){ref-type="fig"}; [@bib3]; [@bib76]; [@bib123]). Importantly, Skd3 has been localized to the mitochondrial intermembrane space ([@bib7]; [@bib49]; [@bib139]). Using GO analysis for biological process, we found that proteins involved in calcium import into mitochondria, chaperone-mediated protein transport, protein insertion into the mitochondrial inner membrane, mitochondrial electron transport, mitochondrial respiratory-chain complex assembly, and cellular response to hypoxia are more insoluble in Skd3 knockout cells compared to wild-type cells ([Figure 7c](#fig7){ref-type="fig"} and [Figure 7---figure supplement 2b](#fig7s2){ref-type="fig"}; [@bib3]; [@bib76]; [@bib123]).

![Skd3 maintains the solubility of key mitochondrial proteins in human cells.\
(**A**) Schematic showing sedimentation assay design. HAP1 cells were lysed and the mitochondrial fraction was separated from the cytosolic fraction. The mitochondrial fraction was then lysed, and the soluble fraction was separated from the insoluble fraction via sedimentation. The samples were then either analyzed via mass-spectrometry or western blotting. (**B**) Volcano plot showing the log~2~ fold change of protein in the Skd3 (*CLPB*) knockout pellet compared to the wild-type (WT) pellet. The 99 proteins that were enriched in the Skd3 pellet are highlighted in red. The 53 proteins that were enriched in the wild-type (WT) pellet are highlighted in green. Significance cutoffs were set as fold change \>2.0 and p\<0.05, indicated with blue dashed lines (N = 3, p\<0.05). (**C**) Select statistically significant terms for GO biological processes from the enriched proteins in the Skd3 knockout pellet. Dashed line shows p=0.05 (p\<0.05). For full list see [Figure 7---figure supplement 2b](#fig7s2){ref-type="fig"}. (**D**) Representative western blot of sedimentation assay showing relative solubility of HAX1 protein in wild-type (WT) and Skd3 (*CLPB*) knockout cells. Results show a marked decrease in HAX1 solubility when Skd3 is knocked out. (N = 3). (**E**) Quantification of HAX1 sedimentation assay shows an overall increase in the insoluble HAX1 relative to the total protein in the Skd3 (*CLPB*) knockout cell line. Quantification is normalized as signal in the pellet divided by the sum of the signal in the pellet and supernatant. The fraction in the pellet for the Skd3 knockout was compared to the wild-type cells using a two-way, unpaired, t-test. (N = 3, individual data points shown as dots, bars show mean ± SEM, \*p\<0.05).](elife-55279-fig7){#fig7}

Specifically, we find that HAX1, OPA1, PHB2, PARL, SMAC/DIABLO, and HTRA2 are more insoluble, which implicates a key role for Skd3 in regulating apoptotic and proteolytic pathways ([@bib5]; [@bib12]; [@bib13]; [@bib16]; [@bib33]; [@bib57]; [@bib99]; [@bib139]). Additionally, the regulators of the mitochondrial calcium uniporter (MCU), MICU1 and MICU2 along with several members of the SLC25 family (including the calcium binding SLC25A25 and SLC25A13) were found to be more insoluble in the knockout compared to the wild type, implicating Skd3 in the regulation of mitochondrial calcium transport and signaling ([@bib2]; [@bib21]; [@bib85]; [@bib88]; [@bib90]; [@bib92]). Indeed, a sedimentation assay as described in [Figure 7a](#fig7){ref-type="fig"} in combination with western blot analysis shows an overall decrease in solubility of MICU2 in mitochondria lacking Skd3 ([Figure 7---figure supplement 3a,b](#fig7s3){ref-type="fig"}). We also observed an enrichment of translocase of the inner membrane (TIM) components, TIMM8A, TIMM8B, TIMM13, TIMM21, TIMM22, TIMM23, and TIMM50 in the insoluble fraction of Skd3 knockouts ([@bib11]; [@bib26]; [@bib36]; [@bib73]; [@bib80]; [@bib87]; [@bib114]; [@bib136]). Finally, we observed an enrichment in respiratory complex I and III proteins and their assembly factors such as NDUFA8, NDUFA11, NDUFA13, NDUFB7, NDUFB10, TTC19, COX11, and CYC1 in the insoluble fraction of Skd3 knockouts ([Figure 6b](#fig6){ref-type="fig"} and [Supplementary file 2](#supp2){ref-type="supplementary-material"}; [@bib1]; [@bib38]; [@bib117]; [@bib120]; [@bib127]). Overall, these results suggest an important role for Skd3 in maintaining the solubility of proteins of the inner mitochondrial membrane and intermembrane space, including key regulators in apoptosis, mitochondrial calcium regulation, protein import, and respiration. Thus, in cells Skd3 appears critical for protein solubility in the intermembrane space and mitochondrial inner membrane.

Skd3 promotes HAX1 solubility in human cells {#s2-7}
--------------------------------------------

HAX1 is a highly-disordered protein that has been previously identified as a Skd3 substrate both in cells and in silico ([Figure 7---figure supplement 4](#fig7s4){ref-type="fig"}; [@bib14]; [@bib134]). HAX1 is an anti-apoptotic BCL-2 family protein that enables efficient cleavage of HTRA2 by PARL to promote cell survival ([@bib13]; [@bib57]). To test if Skd3 regulates HAX1 solubility in human cells, we compared the solubility of HAX1 in wild-type and Skd3-knockout HAP1 cells via sedimentation analysis and western blot. In wild-type cells, HAX1 remained predominantly soluble ([Figure 7d,e](#fig7){ref-type="fig"}). However, when Skd3 was deleted HAX1 became predominantly insoluble ([Figure 7d,e](#fig7){ref-type="fig"}). Thus, Skd3 is essential for HAX1 solubility in cells. Curiously, loss of Skd3 has been previously shown to promote apoptosis in specific contexts ([@bib14]). Furthermore, HAX1 stability has been implicated as a regulator of apoptotic signaling ([@bib5]). Our data support a model whereby Skd3 exerts its anti-apoptotic effect by maintaining HAX1 solubility and contingent functionality.

MGCA7-linked Skd3 variants display diminished disaggregase activity {#s2-8}
-------------------------------------------------------------------

Skd3 has been implicated in a severe mitochondrial disorder, MGCA7, yet little is known about its contribution or function in this disease ([@bib9]; [@bib55]; [@bib56]; [@bib94]; [@bib101]; [@bib135]; [@bib134]). Indeed, many mutations in Skd3 are connected with MGCA7 ([Figure 8a](#fig8){ref-type="fig"}). Most of these are clustered in the NBD, but several are also in the ankyrin-repeat domain, and one frameshift is found in the mitochondrial targeting signal ([Figure 8a](#fig8){ref-type="fig"}). Some MGCA7-linked Skd3 variants, such as R250\* and K321\* (where \* indicates a stop codon), lack the NBD and would be predicted in light of our findings to be incapable protein disaggregation and indeed any ATPase-dependent activities ([Figure 5b,c](#fig5){ref-type="fig"}). We hypothesized that MGCA7-linked missense mutations also directly affect Skd3 disaggregase activity. To test this hypothesis, we purified MGCA7-linked variants of Skd3 from cases where both patient alleles bear the mutation, specifically: T268M, R475Q, A591V, and R650P ([@bib94]). These Skd3 variants cause MGCA7 on a spectrum of clinical severity, which is defined by a scoring system assigned by physicians based on the presentation of various symptoms associated with MGCA7 ([@bib94]). Broadly, the severe phenotype often presented with the absence of voluntary movements in neonates, hyperexcitability, ventilator dependency, and early death ([@bib94]). The ankyrin-repeat variant, T268M, is linked to moderate MGCA7, whereas the NBD variants (R475Q, A591V, and R650P) are linked to severe MGCA7 ([@bib94]).

![Skd3 disaggregase activity predicts the clinical severity of MGCA7-associated mutations.\
(**A**) Domain map depicting all published mutations in Skd3 that have been associated with MGCA7. Mutants in red are studied further here. (**B**) ATPase assay showing the effect of four homozygous MGCA7 mutations on Skd3 activity. ~PARL~Skd3^T268M^ has increased ATPase activity, ~PARL~Skd3^R475Q^ and ~PARL~Skd3^A591V^ have decreased ATPase activity, and ~PARL~Skd3^R650P^ has unchanged ATPase activity compared to wild type. ~PARL~Skd3 MGCA7 mutants ATPase activities were compared to ~PARL~Skd3 wild-type using one-way ANOVA and a Dunnett's multiple comparisons test (N = 3, individual data points shown as dots, bars show mean ± SEM, \*\*\*\*p\<0.0001). (**C**) Luciferase disaggregation/reactivation assay showing the effect of the same four homozygous MGCA7 mutations on Skd3 activity. ~PARL~Skd3^T268M^ had reduced disaggregase activity, whereas ~PARL~Skd3^R475Q^, ~PARL~Skd3^A591V^, and ~PARL~Skd3^R650P^were almost completely inactive compared to wild type. Luciferase activity was buffer subtracted and normalized to Hsp104 plus Hsp70 and Hsp40. Luciferase disaggregase activity was compared to ~PARL~Skd3 wild type using one-way ANOVA and a Dunnett's multiple comparisons test (N = 3, individual data points shown as dots, bars show mean ± SEM, \*\*\*\*p\<0.0001). (**D**) Table summarizing the clinical severity of each MGCA7 mutation as well as the ATPase activity and luciferase disaggregase activity. The table shows a relationship between luciferase disaggregase activity and clinical severity, but no relationship between either the ATPase activity and clinical severity or ATPase and luciferase disaggregase activity. Values represent ATPase activity and luciferase disaggregase activity normalized to wild-type ~PARL~Skd3 activity. Values show mean ± SEM (N = 3).](elife-55279-fig8){#fig8}

Surprisingly, the ATPase activity varied for each MGCA7-linked variant. T268M had significantly increased ATPase activity, R475Q and A591V had marked decreased ATPase activity, and R650P ATPase was indistinguishable from wild type ([Figure 8b](#fig8){ref-type="fig"}). These ATPase activities did not correlate with clinical severity ([Figure 8d](#fig8){ref-type="fig"}; [@bib94]). Thus, Skd3 variant ATPase activity does not accurately predict MGCA7 severity, as the mutation associated with mild MGCA7 had elevated ATPase relative to wild type, whereas different mutations capable of causing severe MGCA7 could exhibit impaired or nearly wild-type ATPase activity.

To address the disconnect between ATPase activity and MGCA7 disease severity, we next tested the disaggregase activity of these MGCA7-linked variants. Strikingly, and in contrast to ATPase activity, we found disaggregase activity tracks closely with disease severity. T268M, the only moderate phenotype variant tested, had \~27% disaggregase activity compared to wild type. By contrast, the three severe MGCA7 variants, R475Q, A591V, and R650P abolish or diminish disaggregation activity with 0%, 0%, and \~4% disaggregation activity compared to wild type, respectively ([Figure 8c](#fig8){ref-type="fig"}). Thus, disaggregase activity but not ATPase activity, is tightly correlated with clinical severity of MGCA7-linked mutations ([Figure 8d](#fig8){ref-type="fig"}; [@bib94]). It will be of interest to test further MGCA7-linked variants to determine whether this trend holds. Nevertheless, our findings suggest that defects in Skd3 protein-disaggregase activity (and not other ATPase-related functions) are the driving factor in MGCA7 and pivotal to human health.

Discussion {#s3}
==========

At the evolutionary transition from protozoa to metazoa, the potent mitochondrial AAA+ protein disaggregase, Hsp78, was lost ([@bib30]). Thus, it has long remained unknown whether metazoan mitochondria disaggregate and reactivate aggregated proteins. Here, we establish that another AAA+ protein, Skd3, is a potent metazoan mitochondrial protein disaggregase. Skd3 is activated by a mitochondrial inner-membrane rhomboid protease, PARL ([Figure 9](#fig9){ref-type="fig"}). PARL removes a hydrophobic auto-inhibitory sequence from the N-terminal region of Skd3, which prior to cleavage may limit Skd3 interactions with substrate ([Figure 9](#fig9){ref-type="fig"}). In this way, Skd3 only becomes fully activated as a disaggregase once it reaches its final cellular destination. Thus, cells might avoid any potential problems that could arise from unchecked Skd3 activity in the wrong cellular location. Skd3 activation by PARL may underlie several potential physiological mechanisms whereby Skd3 is either activated by PARL in response to certain cellular stressors or Skd3 is no longer activated by PARL upon the onset of apoptotic signaling.

![Skd3 is a protein disaggregase that is activated by PARL and inactivated by MGCA7-linked mutations.\
(**A**) Schematic illustrating (**i**) that Skd3 is a protein disaggregase that is activated by PARL cleavage of a hydrophobic auto-inhibitory peptide, (ii) that Skd3 works to solubilize key substrates in the mitochondrial intermembrane space and inner membrane that are involved in apoptosis, protein import, calcium handling, and respiration, and (iii) that mutations in Skd3 associated with MGCA7 result in defective Skd3 disaggregase activity in a manner that predicts the clinical severity of disease.](elife-55279-fig9){#fig9}

Skd3 couples ATP binding and hydrolysis to protein disaggregation. To do so, Skd3 utilizes conserved AAA+ motifs in its NBD, including the Walker A and B motifs to bind and hydrolyze ATP, as well as a conserved pore-loop tyrosine, which likely engages substrate directly in a manner similar to other HCLR clade AAA+ proteins ([@bib31]; [@bib35]; [@bib63]; [@bib70]; [@bib97]; [@bib107]). However, the isolated NBD is insufficient for disaggregase activity, which indicates an important role for the ankyrin-repeat domain. Intriguingly, an ankyrin-repeat domain is also important for the activity of an unrelated ATP-independent protein disaggregase, cpSRP43, where it makes critical contacts with substrate ([@bib54]; [@bib53]; [@bib72]; [@bib82]). Thus, ankyrin-repeat domains appear to be a recurring feature of diverse protein disaggregases.

Importantly, Skd3 is a stand-alone disaggregase and does not require Hsp70 and Hsp40 for maximal activity. This finding is consistent with the absence of Hsp70-interacting domains (NTD, NBD1, and MD) found in Hsp104, which enable collaboration with Hsp70 ([@bib25]; [@bib60]; [@bib118]; [@bib119]). Future structural and biochemical studies will further inform our mechanistic understanding of Skd3 disaggregase activity.

We establish that Skd3 can disaggregate disease-causing α-synuclein fibrils in vitro, demonstrating its robust activity as a disaggregase and identifying it as a potential therapeutic for synucleinopathies. The realization that human cells harbor a AAA+ protein disaggregase of greater potency than Hsp104 opens several therapeutic opportunities. Indeed, Skd3 is expressed in neurons and shifting localization of activated Skd3 to the cytoplasm could help combat cytoplasmic aggregates. Likewise, the expression of the ~PARL~Skd3 enhanced variant in the cytoplasm of dopaminergic neurons may elicit therapeutic benefit similar to Hsp104 and engineered variants in Parkinson's disease models ([@bib50]; [@bib62]; [@bib67]; [@bib69]; [@bib122]). Future studies will further inform our understanding of how to harness Skd3 disaggregase activity therapeutically in synucleinopathies such as Parkinson's disease and other neurodegenerative diseases connected with aberrant protein aggregation.

We demonstrate that Skd3 is essential for maintaining the solubility of mitochondrial inner-membrane and intermembrane space protein complexes and specifically maintains solubility of the anti-apoptotic protein HAX1 in human cells ([Figure 9](#fig9){ref-type="fig"}). We suggest that HAX1 solubility is important for its anti-apoptotic effect. The precise mechanism of regulation between Skd3 and HAX1, PARL, OPA1, HTRA2, and SMAC/DIABLO warrants future study ([Figure 9](#fig9){ref-type="fig"}).

In addition to finding that many human mitochondrial proteins are more insoluble in the absence of Skd3, a small fraction of proteins are more insoluble in the presence of Skd3. Closer analysis of these enriched proteins suggests that many are mitochondrial matrix-associated, especially mitoribosome proteins ([Figure 7b](#fig7){ref-type="fig"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"}). The mitoribosome is a large, megadalton sized protein complex that is much more proteinaceous than its cytoplasmic counterpart and assembles into larger polysomes during active translation ([@bib18]; [@bib42]; [@bib102]). Thus, changes in solubility of the mitoribosome components could be due to increased mitoribosome or polysome assembly in the presence of Skd3.

It is surprising that Skd3 maintains protein solubility in the mitochondrial intermembrane space and inner membrane, as Hsp78 is found in the mitochondrial matrix ([@bib4]; [@bib37]; [@bib78]; [@bib98]; [@bib103]; [@bib129]). Since Skd3 appears in evolution alongside Hsp78 in choanoflagellates it may have initially arisen to serve a distinct function. We hypothesize that the increasing number and complexity of mitochondrial inner membrane protein assemblies (such as MICU1/MICU2/MCU and respiratory complex I) in metazoa might necessitate the requirement of Skd3 activity in the inner mitochondrial membrane and intermembrane space to maintain proteostasis in these compartments ([@bib7]; [@bib49]; [@bib139]).

Hsp78 is known to be involved in mitochondrial protein import in yeast ([@bib78]; [@bib103]). Furthermore, the ankyrin-repeat containing chloroplast disaggregase, cpSRP43, is involved in sorting membrane-targeted cargo ([@bib54]; [@bib53]). It is unknown if Skd3 participates in protein import and sorting in mitochondria. However, given the involvement of two closely related organelle-specific disaggregases in protein import and sorting and the changes in solubility of key TIM components in the absence of Skd3, it is plausible that Skd3 might play a role in protein import and sorting in mitochondria ([Figure 7b,c](#fig7){ref-type="fig"}). Mitochondrial presequences are prone to aggregation and the accumulation of uncleaved precursor aggregates can lead to the activation of an early mitochondrial unfolded protein response (mtUPR) ([@bib29]; [@bib93]; [@bib137]). Skd3 might be required to keep aggregation-prone presequence signals in an unfolded state during import and sorting prior to cleavage or may help disaggregate them if they aggregate. Further investigation is required to determine which changes in protein solubility are driven by defects in Skd3 activity and which are from potential defects in mitochondrial protein import or membrane insertion.

Mutations in Skd3 are connected to MGCA7, which can be a devastating disorder involving severe neurologic deterioration, neutropenia, and death in infants ([@bib135]). Importantly, we establish that diverse MGCA7-linked mutations in Skd3 impair disaggregase activity, but not necessarily ATPase activity ([Figure 9](#fig9){ref-type="fig"}). The degree of impaired disaggregase activity predicts the clinical severity of the disease, which suggests that disaggregase activity is a critical factor in disease. However, it is yet unclear which Skd3 substrate or substrates contribute to the MGCA7 etiology. Our mass-spectrometry data suggest that MGCA7 arises due to severely compromised proteostasis in the mitochondrial inner-membrane and intermembrane space ([Figure 9](#fig9){ref-type="fig"}). Hence, small-molecule drugs that restore wild-type levels of disaggregase activity to MGCA7-linked Skd3 variants could be valuable therapeutics.

Finally, Skd3 has also emerged as a factor in Venetoclax resistance, a FDA-approved drug for the treatment of acute myeloid leukemia (AML), which exerts its mechanism via BCL-2 inhibition ([@bib14]). These studies suggest that inhibition of Skd3 may be of critical therapeutic importance for treating Venetoclax-resistant cancers ([@bib14]). Small-molecule screens targeted at finding inhibitors of Skd3 disaggregase activity may yield important drugs for Venetoclax-resistant AML patients. Thus, the Skd3 disaggregase assays established in this study could provide a powerful platform for isolating therapeutic compounds for MGCA7 and AML.

Materials and methods {#s4}
=====================

Multiple sequence alignments {#s4-1}
----------------------------

NBD sequences were acquired via UniProtKB for *Homo sapiens* Skd3, *Saccharomyces cerevisiae* Hsp104, *Saccharomyces cerevisiae* Hsp78, *Escherichia coli* ClpB, *Escherichia coli* ClpA, and *Staphylococcus aureus* ClpC. Skd3 sequences were acquired via SMART protein domain annotation resource ([@bib61]). Sequences from *Anolis carolinensis*, *Bos taurus*, *Callithrix jacchus*, *Canis lupus*, *Capra hircus*, *Danio rerio*, *Equus caballus*, *Geospiza fortis*, *Gorilla gorilla*, *Homo sapiens*, *Monosiga brevicollis*, *Mus musculus*, *Nothobranchius rachovii*, *Rattus norvegicus*, *Sus scrofa*, *Trachymyrmex septentrionalis*, *Trichinella papuae*, and *Xenopus laevis* were used to generate alignment for [Figure 1](#fig1){ref-type="fig"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"}. Compiled sequences were aligned and made into a guide tree via Clustal Omega ([@bib68]). Alignment image was generated via BoxShade tool ([@bib48]). Guide tree image was built using FigTree ([@bib96]). Species images were used under license via PhyloPic. Sequence logo was created using WebLogo and 42 mammalian Skd3 protein sequences (*Ailuropoda melanoleuca*, *Callorhinus ursinus*, *Canis lupus*, *Carlito syrichta*, *Cebus capucinus*, *Ceratotherium simum*, *Cercocebus atys*, *Chlorocebus sabaeus*, *Colobus angolensis*, *Equus asinus, Equus caballus*, *Equus przewalskii*, *Felis catus*, *Gorilla gorilla*, *Gulo gulo*, *Grammomys surdaster*, *Homo sapiens*, *Macaca fascicularis*, *Macaca mulatta*, *Macaca nemestrina*, *Mandrillus leucophaeus*, *Microcebus murinus*, *Microtus ochrogaster*, *Mustela putorius*, *Nomascus leucogenys*, *Odobenus rosmarus*, *Orycteropus afer*, *Pan paniscus*, *Pan troglodyte*, *Panthera tigris*, *Papio anubis*, *Piliocolobus tephrosceles*, *Pongo abelii*, *Propithecus coquereli*, *Puma concolor*, *Rhinopithecus bieti*, *Rhinopithecus roxellana*, *Rousettus aegyptiacus*, *Theropithecus gelada*, *Ursus arctos*, *Ursus maritimus*, and *Zalophus californianus*) ([@bib20]; [@bib105]).

Cloning MBP-Skd3 plasmids {#s4-2}
-------------------------

~MPP~Skd3, ~PARL~Skd3, ~ANK~Skd3, and ~NBD2~Skd3 were cloned into the pMAL C2 plasmid with TEV site ([@bib140]) using Gibson assembly ([@bib39]). The mitochondrial targeting signal was identified using MitoProt in agreement with previous work ([@bib17]; [@bib134]). Site-directed mutagenesis was performed using QuikChange site-directed mutagenesis (Agilent) and confirmed by DNA sequencing.

Purification of Skd3 {#s4-3}
--------------------

Skd3 variants were expressed as an N-terminally MBP-tagged protein in BL21 (DE3) RIL cells (Agilent). Cells were lysed via sonication in 40 mM HEPES-KOH pH = 7.4, 500 mM KCl, 20% (w/v) glycerol, 5 mM ATP, 10 mM MgCl~2~, 2 mM β-mercaptoethanol, 2.5 µM PepstatinA, and cOmplete Protease Inhibitor Cocktail (one tablet/250 mL, Millipore Sigma). Lysates were centrifuged at 30,597xg and 4°C for 20 min and the supernatant was applied to amylose resin (NEB). The column was washed with 15 column volumes (CV) of wash buffer (WB: 40 mM HEPES-KOH pH = 7.4, 500 mM KCl, 20% (w/v) glycerol, 5 mM ATP, 10 mM MgCl~2~, 2 mM β-mercaptoethanol, 2.5 µM PepstatinA, and cOmplete Protease Inhibitor Cocktail) at 4°C, 3 CV of WB supplemented with 20 mM ATP at 25°C for 30 min, and 15 CV of WB at 4°C. The protein was then exchanged into elution buffer (EB: 50 mM Tris-HCl pH = 8.0, 300 mM KCl, 10% glycerol, 5 mM ATP, 10 mM MgCl~2~, and 2 mM β-mercaptoethanol) with 8 CV and eluted via TEV cleavage at 34°C. The protein was then run over a size exclusion column (GE Healthcare HiPrep 26/60 Sephacryl S-300 HR) in sizing buffer (50 mM Tris-HCl pH = 8.0, 500 mM KCl, 10% glycerol, 1 mM ATP, 10 mM MgCl~2~, and 1 mM DTT). Peak fractions were collected, concentrated to \>5 mg/mL, supplemented with 5 mM ATP, and snap frozen. Protein purity was determined to be \>95% by SDS-PAGE and Coomassie staining.

Purification of Hsp104 {#s4-4}
----------------------

Hsp104 was purified as previously described ([@bib25]). In brief, Hsp104 was expressed in BL21 (DE3) RIL cells, lysed via sonication in lysis buffer \[50 mM Tris-HCl pH = 8.0, 10 mM MgCl~2~, 2.5% glycerol, 2 mM β-mercaptoethanol, 2.5 µM PepstatinA, and cOmplete Protease Inhibitor Cocktail (one mini EDTA-free tablet/50 mL, Millipore Sigma)\], clarified via centrifugation at 30,597xg and 4°C for 20 min, and purified on Affi-Gel Blue Gel (Bio-Rad). Hsp104 was eluted in elution buffer (50 mM Tris-HCl pH = 8.0, 1M KCl, 10 mM MgCl~2~, 2.5% glycerol, and 2 mM β-mercaptoethanol) and then exchanged into storage buffer (40 mM HEPES-KOH pH = 7.4, 500 mM KCl, 20 mM MgCl~2~, 10% glycerol, 1 mM DTT). The protein was diluted to 10% in buffer Q (20 mM Tris-HCl pH = 8.0, 50 mM NaCl, 5 mM MgCl~2~, and 0.5 mM EDTA) and loaded onto a 5 mL RESOURCE Q anion exchange chromatography (GE Healthcare). Hsp104 was eluted via linear gradient of buffer Q+ (20 mM Tris pH = 8.0, 1M NaCl, 5 mM MgCl~2~, and 0.5 mM EDTA). The protein was then exchanged into storage buffer and snap frozen. Protein purity was determined to be \>95% by SDS-PAGE and Coomassie staining.

Purification of Hsc70 and Hdj1 {#s4-5}
------------------------------

Hsc70 and Hdj1 were purified as previously described ([@bib77]). Hsc70 and Hdj1 were expressed in BL21 (DE3) RIL cells with an N-terminal His-SUMO tag. Cells were lysed via sonication into lysis buffer \[50 mM HEPES-KOH pH = 7.5, 750 mM KCl, 5 mM MgCl~2~, 10% glycerol, 20 mM imidazole, 2 mM β-mercaptoethanol, 5 µM pepstatin A, and cOmplete Protease Inhibitor Cocktail (one mini EDTA-free tablet/50 mL)\]. Lysates were centrifuged at 30,597xg and 4°C for 20 min and the supernatant was bound to Ni-NTA Agarose resin (Qiagen), washed with 10 CV of wash buffer (50 mM HEPES-KOH pH = 7.5, 750 mM KCl, 10 mM MgCl~2~, 10% glycerol, 20 mM imidazole, 1 mM ATP, and 2 mM β-mercaptoethanol), and then eluted with 2 CV of elution buffer (wash buffer supplemented with 300 mM imidazole). The tag was removed via Ulp1 (1:100 Ulp1:Protein molar ratio) cleavage during dialysis into wash buffer. The protein was further purified via loading onto a 5 mL HisTrap HP column (GE Healthcare) and pooling the untagged elution. Cleaved protein was pooled, concentrated, purified further by Resource Q ion exchange chromatography, and snap frozen. Protein purity was determined to be \>95% by SDS-PAGE and Coomassie staining.

ATPase assays {#s4-6}
-------------

Proteins (0.25 µM monomer) were incubated with ATP (1 mM) (Innova Biosciences) at 37°C for 5 min (or otherwise indicated) in luciferase reactivation buffer (LRB; 25 mM HEPES-KOH \[pH = 8.0\], 150 mM KAOc, 10 mM MgAOc, 10 mM DTT). For substrate-stimulation of ATPase activity the indicated concentration of substrate was added. ATPase activity was assessed via inorganic phosphate release with a malachite green detection assay (Expedeon) and measured in Nunc 96 Well Optical plates on a Tecan Infinite M1000 plate reader. Background hydrolysis was measured at time zero and subtracted ([@bib24]).

Luciferase disaggregation and reactivation assays {#s4-7}
-------------------------------------------------

Firefly luciferase aggregates were formed by incubating luciferase (50 µM) in LRB (pH=7.4) plus 8M urea at 30°C for 30 min. The luciferase was then rapidly diluted 100-fold into LRB, snap frozen, and stored at −80°C until use. Hsp104 and Skd3 variants (1 µM monomer, unless otherwise indicated) were incubated with 50 nM aggregated firefly luciferase in the presence or absence of Hsc70 and Hdj2 (0.167 µM each) in LRB plus 5 mM ATP plus an ATP regeneration system (ARS; 1 mM creatine phosphate and 0.25 µM creatine kinase) at 37°C for 90 min (unless otherwise indicated). The nucleotide-dependence of Skd3 disaggregation activity was tested in the presence of ATP (Sigma), AMP-PNP (Roche), ATPγS (Roche), or ADP (MP Biomedicals) for 30 min at 37°C without ARS. Recovered luminescence was monitored in Nunc 96 Well Optical plates using a Tecan Infinite M1000 plate reader ([@bib24]).

α-Synuclein disaggregation assay {#s4-8}
--------------------------------

α-Synuclein fibrils were acquired from the Luk lab and formed as previously described ([@bib64]). ~PARL~Skd3 (10 μM monomer) was incubated with α-synuclein fibrils (0.5 μM monomer) in LRB in the presence or absence of ARS (10 mM ATP, 10 mM creatine phosphate, 40 μg/mL creatine kinase) at 37°C for 90 min. The samples were then centrifuged at 4°C and 20,000xg for 20 min. After centrifugation the supernatants were pipetted off of the pellets and the pellets were boiled in Pellet Buffer (PB; 50 mM Tris-HCl \[pH = 8.0\], 8M Urea, 150 mM NaCl, 10 uL/1 mL mammalian PI cocktail \[Sigma CAT\# P8340\]) for 5 min at 99°C. The total sample, supernatant, and pellet samples were then blotted on nitrocellulose membrane (ThermoFisher Scientific CAT\# 88018) and incubated with the SYN211 antibody (ThermoFisher Scientific CAT\# AHB0261). Blots were then incubated with the IRDye 800CW Goat anti-Mouse IgG Secondary Antibody (Li-COR CAT\# 926--32210) and imaged using the Li-Cor Odyssey Fc Imaging System. Samples were quantified using FIJI and normalized as (signal in supernatant)/(signal in pellet + signal in supernatant).

Western blots {#s4-9}
-------------

Mammalian whole cell lysates were prepared by boiling 500,000 cells in 1x Sample Buffer (SB; 60 mM Tris-HCl \[pH = 6.8\], 5% glycerol, 2% SDS, 10% β-mercaptoethanol, 0.025% bromophenol blue, 1x Mammalian PI cocktail) for 5 min at 99°C. Sedimentation assay samples were prepared as described above. Western blot samples were boiled for 5 min at 99°C in 1x SB, separated by SDS-PAGE on a gradient gel (4%--20%, Bio-Rad CAT\# 3450033), and transferred to a PVDF membrane. Membranes were blocked in Odyssey Blocking Buffer in PBS (Li-Cor CAT\# 927--40000) for 1 hr at 25°C. Blots were then incubated in primary antibody overnight at 4°C and then in secondary for 30 min at 25°C. The antibodies used were: α-CLPB (Abcam CAT\# ab235349), α-HAX1 (Abcam CAT\# ab137613), α-COXIV (Abcam CAT\# ab14744), α-GAPDH (Abcam CAT\# ab8245), α-MICU2 (Abcam CAT\# ab101465), IRDye 800CW Goat α-mouse secondary (Li-Cor CAT\# 926--32210), and IRDye 680RD Goat α-rabbit secondary (Li-Cor CAT\# 926--68071). Blots were imaged on a Li-Cor Odyssey Fc Imaging System.

Mammalian cell culture {#s4-10}
----------------------

Isogenic HAP1 and HAP1 Δ*CLPB* cells were acquired directly from Horizon Discovery (CAT\# HZGHC81570 and HZGHC007326c001) and have been control quality checked by the vendor. HAP1 cells are a human near-haploid cell line derived from the male chronic myelogenous leukemia (CML) cell line KBM-7 ([@bib32]). In brief, the *CLPB* knockout line was generated via CRISPR-Cas9 and the gRNA TGGCACGGGCAGCTTCCAAC to make a 1 bp insertion into exon 2 of the *CLPB* gene. Knockout was confirmed by Sanger sequencing (DNA) by the vendor and western blot ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). Cells were maintained in IMDM (Gibco CAT\# 12440053) supplemented with 10% FBS (GE CAT\# SH3007003) and 1% P/S (Gibco CAT\# 15140122) at 37°C and 5% CO~2~. Cells were grown at a confluency of 50--60% for mitochondrial isolation.

Mitochondrial isolation {#s4-11}
-----------------------

Mitochondria were isolated as previously described ([@bib34]). In brief, 50--100\*10^6^ cells were resuspended in 5 mL SM buffer (50 mM Tris-HCl \[pH = 7.4\], 0.25M sucrose, 2 mM EDTA, and 1% BSA) and homogenized with a Dounce homogenizer and Teflon pestle (30 strokes at 600 RPM) at 4°C. Lysate was then centrifuged at 600xg for 10 min. The supernatant was collected, and the pellet was dissolved in 5 mL SM buffer and homogenized (15 strokes at 600 RPM). Sample was then centrifuged at 600xg for 10 min and the supernatant was pooled and centrifuged at 12,000xg for 15 min. The pellet was collected and used for further experiments.

Mitochondrial sedimentation assay {#s4-12}
---------------------------------

Mitochondrial sedimentation assay was performed essentially as previously described ([@bib132]). 60--80 μg isolated mitochondria were resuspended in 200 μL Mitochondrial Resuspension Buffer (40 mM HEPES-KOH, pH = 7.6, 500 mM sucrose, 120 mM K-acetate, 10 mM Mg-acetate, 5 mM glutamate, 5 mM malate, 5 mM EDTA, 5 mM ATP, 20 mM creatine phosphate, 4 μg/mL creatine kinase, 1 mM DTT) and incubated at 37°C for 20 min. The mitochondria were then pelleted at 12,000xg for 10 min at 4°C. The mitochondria were then resuspended in 200 μL Lysis Buffer (30 mM Tris-HCl, pH = 7.4, 200 mM KCl, 0.5% v/v Triton X-100, 5 mM EDTA, 0.5 mM PMSF, 1x Mammalian PI cocktail) and lysed in a thermomixer at 2,000 RPM for 10 min at 4°C. The protein concentration of the lysate was then quantified using a BCA assay (ThermoFisher CAT\# 23225). 12 μg of lysate was added to a total volume of 50 μL Lysis Buffer and reserved as a total protein sample. 12 μg of lysate was added to a total volume of 50 μL Lysis Buffer and sedimented at 20,000xg for 20 min at 4°C. The supernatant was removed, TCA precipitated, and frozen for later processing. The pellet was boiled in 10 μL of Pellet Buffer and frozen for later processing.

Mass spectrometry {#s4-13}
-----------------

Pellet samples were excised as whole lanes from gels, reduced with TCEP, alkylated with iodoacetamide, and digested with trypsin. Tryptic digests were desalted by loading onto a MonoCap C18 Trap Column (GL Sciences), flushed for 5 min at 6 μL/min using 100% Buffer A (H~2~0, 0.1% formic acid), then analyzed via LC (Waters NanoAcquity) gradient using Buffer A and Buffer B (acetonitrile, 0.1% formic acid) (initial 5% B; 75 min 30% B; 80 min 80% B; 90.5--105 min 5% B) on the Thermo Q Exactive HF mass spectrometer. Data were acquired in data-dependent mode. Analysis was performed with the following settings: MS1 60K resolution, AGC target 3e6, max inject time 50 ms; MS2 Top N = 20 15K resolution, AGC target 5e4, max inject time 50 ms, isolation window = 1.5 m/z, normalized collision energy 28%. LC-MS/MS data were searched with full tryptic specificity against the UniProt human database using MaxQuant 1.6.8.0. MS data were also searched for common protein N-terminal acetylation and methionine oxidation. Protein and peptide false discovery rate was set at 1%. LFQ intensity was calculated using the MaxLFQ algorithm ([@bib19]). Fold enrichment was calculated as LFQ intensity from the Δ*CLPB* pellet divided by the LFQ intensity from the wild-type pellet. High confidence hits were quantified as minimum absolute fold change of 2 and p-value\<0.05.
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###### Alignment of Skd3 to diverse metazoan lineages shows conservation of key motifs and domains.

Alignment of Skd3 protein from diverse metazoan lineages. Alignment was constructed using Clustal Omega. Alignment shows high level of conservation of Skd3 among species. *H. sapiens*, *G. gorilla*, and *C. jacchus* Skd3 have an additional insertion in the ankyrin-repeat domain that is not conserved in the other species. This alignment was used to generate the phylogenetic tree in [Figure 1B](#fig1){ref-type="fig"}. The protozoan *M. brevicollis* Skd3 sequence was included in the alignment for reference. MTS (mitochondrial-targeting sequence, ANK (ankyrin-repeat domain), NBD (nucleotide-binding domain), and CTD (C-terminal domain).

###### Proteins enriched in HAP1 *ΔCLPB* pellet.

Proteins from mass spectrometry data in [Figure 7b](#fig7){ref-type="fig"} highlighted in red that have \>2.0 fold change increase in the *ΔCLPB* insoluble fraction compared to wild type and a p-value of \<0.05.

###### Proteins enriched in HAP1 WT pellet.

Proteins from mass spectrometry data in [Figure 7b](#fig7){ref-type="fig"} highlighted in green that have \>2.0 fold change increase in the wild-type insoluble fraction compared to *ΔCLPB* and a p-value of \<0.05.

Data availability {#s7}
=================

All data generated or analysed during this study are included in the manuscript and supporting files.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species) or resource   Designation                                             Source or reference                                              Identifiers                                                                  Additional information
  ------------------------------------ ------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Antibody                             Mouse monoclonal α-α-synuclein (SYN211)                 ThermoFisher Scientific                                          AHB0261; RRID:[AB_10978319](https://scicrunch.org/resolver/AB_10978319)      (1:500 dilution)

  Antibody                             Rabbit polyclonal α-CLPB (Skd3)                         abcam                                                            ab235349; RRID:[AB_2847899](https://scicrunch.org/resolver/AB_2847899)       (1:1000 dilution)

  Antibody                             Rabbit polyclonal α-CLPB (Skd3)                         abcam                                                            ab76179; RRID:[AB_1310087](https://scicrunch.org/resolver/AB_1310087)        (1:1000 dilution)

  Antibody                             Rabbit polyclonal α-CLPB (Skd3)                         abcam                                                            ab87253; RRID:[AB_1952530](https://scicrunch.org/resolver/AB_1952530)        (1:1000 dilution)

  Antibody                             Rabbit polyclonal α-CLPB (Skd3)                         Proteintech                                                      15743--1-AP; RRID:[AB_2847900](https://scicrunch.org/resolver/AB_2847900)    (1:1000 dilution)

  Antibody                             Mouse monoclonal\                                       abcam                                                            ab14744; RRID:[AB_301443](https://scicrunch.org/resolver/AB_301443)          (1:1000 dilution)
                                       α-COXIV                                                                                                                                                                                               

  Antibody                             Mouse monoclonal α-GAPDH                                abcam                                                            ab8245; RRID:[AB_2107448](https://scicrunch.org/resolver/AB_2107448)         (1:1000 dilution)

  Antibody                             Rabbit polyclonal α-HAX1                                abcam                                                            ab137613; RRID:[AB_2847902](https://scicrunch.org/resolver/AB_2847902)       (1:500 dilution)

  Antibody                             Rabbit polyclonal\                                      abcam                                                            ab101465; RRID:[AB_10711219](https://scicrunch.org/resolver/AB_10711219)     (1:1000 dilution)
                                       α-MICU2                                                                                                                                                                                               

  Antibody                             IRDye 680RD Goat anti-Rabbit IgG Secondary Antibody     Li-Cor                                                           926--68071; RRID:[AB_10956166](https://scicrunch.org/resolver/AB_10956166)   (1:2500 dilution)

  Antibody                             IRDye 800CW Goat anti-Mouse IgG Secondary Antibody      Li-Cor                                                           926--32210; RRID:[AB_621842](https://scicrunch.org/resolver/AB_621842)       (1:2500 dilution)

  Cell line (*Escherichia coli*)       BL21-CodonPlus (DE3)\                                   Agilent                                                          230245                                                                       Chemically competent cells
                                       -RIL competent cells                                                                                                                                                                                  

  Cell line (*Homo sapiens*)           Human HAP1 Knockout Cell Lines - WT                     Horizon Discovery                                                HZGHC81570;; RRID:[CVCL_Y019](https://scicrunch.org/resolver/CVCL_Y019)      Human control cell line. The HAP1 cell line was bought directly from Horizon Discovery and has been control quality checked by the vendor.

  Cell line (*Homo sapiens*)           Human HAP1 Knockout Cell Lines - CLPB                   Horizon Discovery                                                HZGHC007326c001                                                              Human knockout cell line. The HAP1 ClpB knockout cell line was bought directly from Horizon Discovery and has been control quality checked by the vendor.

  Commercial assay or kit              ATPase Activity Kit (Colorimetric)                      Innova Biosciencens                                              601--0120                                                                    

  Commercial assay or kit              Luciferase Assay Reagent                                Promega                                                          E1483                                                                        

  Chemical compound, drug              Creatine phosphate                                      Roche                                                            10621722001                                                                  

  Chemical compound, drug              ADP                                                     MP Biomedicals                                                   150260                                                                       

  Chemical compound, drug              AMPPNP                                                  Roche                                                            10102547001                                                                  

  Chemical compound, drug              ATP                                                     Sigma-Aldrich                                                    A3377                                                                        

  Chemical compound, drug              ATPγS                                                   Roche                                                            10102342001                                                                  

  Chemical compound, drug              cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail   Sigma-Aldrich                                                    4693159001                                                                   

  Chemical compound, drug              Pepstatin A, microbial,≥90% (HPLC)                      Sigma-Aldrich                                                    P5318                                                                        

  Chemical compound, drug              Protease Inhibitor Cocktail (mammalian)                 Sigma-Aldrich                                                    P8340                                                                        

  Gene (*Homo sapiens*)                *CLPB*                                                  NA                                                               HGNC:30664                                                                   

  Peptide, recombinant protein         α-synuclein fibrils                                     [@bib64]                                                                                                                                      Preformed α-synuclein fibrils were a gift from Kelvin Luk.

  Peptide, recombinant protein         β-casein                                                Sigma-Aldrich                                                    C6905                                                                        

  Peptide, recombinant protein         Creatine kinase                                         Roche                                                            10127566001                                                                  

  Peptide, recombinant protein         Firefly luciferase                                      Sigma-Aldrich                                                    L9506                                                                        

  Peptide, recombinant protein         Hdj1                                                    [@bib77]                                                                                                                                      

  Peptide, recombinant protein         Hsc70                                                   [@bib77]                                                                                                                                      

  Peptide, recombinant protein         Hsp104                                                  [@bib24] and [@bib50]                                                                                                                         

  Peptide, recombinant protein         Lysozyme                                                Sigma-Aldrich                                                    L6876                                                                        

  Peptide, recombinant protein         ~MPP~Skd3                                               This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Peptide, recombinant protein         ~MPP~Skd3^K387A^                                        This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Peptide, recombinant protein         ~MPP~Skd3^E455Q^                                        This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Peptide, recombinant protein         ~MPP~Skd3^Y430A^                                        This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Peptide, recombinant protein         ~PARL~Skd3                                              This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Peptide, recombinant protein         ~PARL~Skd3^K387A^                                       This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Peptide, recombinant protein         ~PARL~Skd3^E455Q^                                       This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Peptide, recombinant protein         ~PARL~Skd3^Y430A^                                       This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Peptide, recombinant protein         ~PARL~Skd3^T268M^                                       This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Peptide, recombinant protein         ~PARL~Skd3^R475Q^                                       This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Peptide, recombinant protein         ~PARL~Skd3^A591V^                                       This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Peptide, recombinant protein         ~PARL~Skd3^R650P^                                       This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Peptide, recombinant protein         Skd3~ANK~                                               This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Peptide, recombinant protein         Skd3~NBD~                                               This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Recombinant DNA reagent              Hdj1 in pE-SUMO                                         [@bib77]                                                                                                                                      

  Recombinant DNA reagent              Hsc70 in pE-SUMO                                        [@bib77]                                                                                                                                      

  Recombinant DNA reagent              Hsp104 in pNOTAG                                        [@bib24] and [@bib50]                                                                                                                         

  Recombinant DNA reagent              ~MPP~Skd3 in pMAL C2 with TEV site                      This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Recombinant DNA reagent              ~MPP~Skd3^K387A^ in pMAL C2 with TEV site               This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Recombinant DNA reagent              ~MPP~Skd3^E455Q^ in pMAL C2 with TEV site               This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Recombinant DNA reagent              ~MPP~Skd3^Y430A^ in pMAL C2 with TEV site               This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Recombinant DNA reagent              ~PARL~Skd3 in pMAL C2 with TEV site                     This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Recombinant DNA reagent              ~PARL~Skd3^K387A^ in pMAL C2 with TEV site              This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Recombinant DNA reagent              ~PARL~Skd3^E455Q^ in pMAL C2 with TEV site              This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Recombinant DNA reagent              ~PARL~Skd3^Y430A^ in pMAL C2 with TEV site              This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Recombinant DNA reagent              ~PARL~Skd3^T268M^ in pMAL C2 with TEV site              This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Recombinant DNA reagent              ~PARL~Skd3^R475Q^ in pMAL\                              This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3
                                       C2 with TEV site                                                                                                                                                                                      

  Recombinant DNA reagent              ~PARL~Skd3^A591V^ in pMAL C2 with TEV site              This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Recombinant DNA reagent              ~PARL~Skd3^R650P^ in pMAL C2 with TEV site              This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Recombinant DNA reagent              Skd3~ANK~ in pMAL C2 with TEV site                      This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Recombinant DNA reagent              Skd3~NBD~ in pMAL C2 with TEV site                      This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               ClpA (*Escherichia coli*)                               This study                                                       UniProtKB:P0ABH9                                                             Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               ClpB (*Escherichia coli*)                               This study                                                       UniProtKB:P63284                                                             Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               ClpC (*Staphylococcus aureus*)                          This study                                                       UniProtKB:Q2G0P5                                                             Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Hsp104 (*Saccharomyces cerevisiae*)                     This study                                                       UniProtKB:P31539                                                             Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Hsp78 (*Saccharomyces cerevisiae*)                      This study                                                       UniProtKB:P33416                                                             Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               HAX1 (*Homo sapiens*)                                   This study                                                       UniProtKB:O00165                                                             Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Ailuropoda melanoleuca*)                         This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Anolis carolinensis*)                            This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Bos taurus*)                                     This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Callithrix jacchus*)                             This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Callorhinus ursinus*)                            This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Canis lupus*)                                    This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Capra hircus*)                                   This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Carlito syrichta*)                               This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Cebus capucinus*)                                This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Ceratotherium simum*)                            This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Cercocebus atys*)                                This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Chlorocebus sabaeus*)                            This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Colobus angolensis*)                             This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Danio rerio*)                                    This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Equus asinus*)                                   This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Equus caballus*)                                 This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Equus przewalskii*)                              This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Felis catus*)                                    This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Geospiza fortis*)                                This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Gorilla gorilla*)                                This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Gulo gulo*)                                      This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Grammomys surdaster*)                            This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Homo sapiens)*                                   This study                                                       UniProtKB:Q9H078                                                             Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Macaca fascicularis*)                            This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Macaca mulatta*)                                 This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Macaca nemestrina*)                              This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Mandrillus leucophaeus*)                         This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Microcebus murinus*)                             This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Microtus ochrogaster*)                           This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Monosigia brevicollis*)                          This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Mus musculus*)                                   This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Mustela putorius*)                               This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Nomascus leucogenys*)                            This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Nothobranchius rachovii*)                        This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Odobenus rosmarus*)                              This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Orycteropus afer*)                               This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Pan paniscus*)                                   This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Pan troglodyte*)                                 This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Panthera tigris*)                                This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Papio anubis*)                                   This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent\              Skd3\                                                   This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3
                                       (*Piliocolobus tephrosceles*)                                                                                                                                                                         

  Sequence-based reagent               Skd3 (*Pongo abelii*)                                   This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Propithecus coquereli*)                          This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Puma concolor*)                                  This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Rattus norvegicus*)                              This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Rhinopithecus bieti*)                            This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Rhinopithecus roxellana*)                        This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Rousettus aegyptiacus*)                          This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Sus scrofa*)                                     This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Theropithecus gelada*)                           This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Trachymyrmex septentrionalis*)                   This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Trichinella papuae*)                             This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Ursus arctos*)                                   This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Ursus maritimus*)                                This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Xenopus laevis*)                                 This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Sequence-based reagent               Skd3 (*Zalophus californianus*)                         This study                                                                                                                                    Full description can be found in Materials and methods: Purification of Skd3

  Software, algorithm                  BOXSHADE                                                [@bib48]                                                                                                                                      

  Software, algorithm                  Clusal Omega                                            [@bib68]                                                                                                                                      
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

Skd3 is a mitochondrial AAA+ enzyme whose function has been poorly-understood. The authors reveal that Skd3 is capable of both reactivating a model aggregated luciferase substrate and solubilizing α-synuclein in vitro. The in vitro activity of Skd3 is shown to be enhanced by the proteolytic cleavage of an autoinhibitory peptide, which is removed by the PARL protease in mitochondria. Useful mechanistic insights are also provided into some of the known disease-associated mutations in Skd3. Overall, the findings are of significant interest, as they address long-standing questions concerning the function of Skd3 and how metazoans handle mitochondrial aggregation in the absence of Hsp110 and Hsp78.

**Decision letter after peer review:**

Thank you for submitting your article \"Skd3 is a potent mitochondrial protein disaggregase that is inactivated by 3-methylglutaconic aciduria-linked mutations\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Huda Zoghbi as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Steven Glynn (Reviewer \#1).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Skd3 is a mitochondrial AAA+ enzyme whose function has been poorly-understood. The authors reveal that Skd3 is capable of reactivating a model luciferase aggregate and solubilizing α-synuclein in vitro. The in vitro activity of Skd3 is shown to be enhanced by the proteolytic cleavage of an autoinhibitory peptide, which is removed by the PARL protease in mitochondria. Loss of SKD3 in human mitochondria is found to decrease the solubility of several specific proteins in the intermembrane space, although it is unclear whether this is a direct effect. The experiments employed are straight-forward and a full analysis of SKD3 activity, including the identify of its physiological substrates, will require further studies.

The study is carefully done, and the manuscript is well-written. Although a recent study reported a similar finding (i.e., that Skd3 serves as disaggregase), the present study is substantially more thorough and validates at least some of the in vitro findings in the cellular context. The work also provides useful mechanistic insights into some of the known disease-associated mutations in Skd3. Overall, the findings are of significant interest in addressing long-standing questions concerning the function of Skd3 and how metazoans handle mitochondrial aggregation in the absence of Hsp110 and Hsp78. This said, the study falls short on demonstrating true disaggregation activity in vitro and in vivo, behaviors that ideally would need to be validated before publication is warranted.

While this review was being finalized, the complexities of COVID-19 emerged. Given these recent developments, the reviewers recognize that the additional experiments they initially requested may not be possible. We would therefore ask that the authors first read the \'original\' review for a sense of the issues raised by the reviewers, and then the \'updated\' review, which follows for a revised set of requests.

Essential revisions:

1\) The authors demonstrate that Skd3 reactivates thermally inactivated luciferase but do not show directly that Skd3 actually dissociates luciferase aggregates (the solubilization of α-synuclein in Figure 4 is insufficient to demonstrate such an activity because the experiments never start with the isolated fibrils only and no equivalent experiments are shown with luciferase). An in vitro test for disaggregation activity (e.g., spinning down and quantifying aggregates as a function of Skd3 activity) is necessary to validate the primary point of the manuscript.

2\) Similar to (1), the authors should show that Skd3 is able to disaggregate proteins in vivo (the increased solubility of HAX1 in Figure 7 is insufficient to demonstrate such an activity because it cannot distinguish between whether Skd3 resolves aggregation or prevents aggregation from happening in the first place). One approach that might be of use is that of Janowsky et al., who showed that mitochondrial Hsp78 was to induce thermal aggregation of an imported protein in purified mitochondria and then monitor disaggregation +/- Hsp78 (von Janowsky et al., 2006). Other work by Liberek provides some alternative approaches.

3\) The changes in mitochondrial protein solubility observed in SKD3 knockout cells could be caused by loss of SKD3 disaggregase activity on specific proteins or secondary defects in protein import or membrane integration leading to accumulation of misfolded/uninserted proteins in the IMS. The authors should address this question in the Discussion.

4\) The loss of ATPase and disaggregase activity seen for the isolated NBD domain (SKD3NBD) could be explained by disassembly of SKD3 hexamers in the absence of the ankyrin domains. The authors should include information on whether these constructs form stable hexamers.

5\) Figures 2C/E and 3C/E: Instead of normalized data, it is important to show the real reactivation data. Are 1% or 50% of luciferase molecules reactivatable with Skd3 in this set up?

6\) No direct evidence has been presented that the pore-loop Y430 makes direct contact with the substrate, hence it seems an overreach to claim that the conserved tyrosine binds the substrate. This statement should be qualified or better supported.

7\) Some additional mutants should be tested before concluding that disaggregase activity correlates with disease severity (a term that needs to be defined). Otherwise, this claim should be toned down.

Updated Essential revisions in light of COVID-19:

1\) Please address as many points as possible raised in the original summary.

2\) Regarding Essential revision \#1, above -- the in vitro data can be strengthened by improved data analysis and discussion of the limitations, which should be possible without additional experiments. Specifically, the amount of luciferase as a % of total activity prior to aggregation should be reported to help support the idea that Skd3 is a robust disaggregase. Please also comment on the estimated fraction of α-synuclein present in fibrils in at the start of the in vitro disaggregation assay.

3\) Regarding Essential revision \#2, above -- the fact that the in vivo experiments in Figure 7 do not distinguish between disaggregation and maintaining protein solubility should be directly addressed in the Discussion.
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Author response

> \[...\] Overall, the findings are of significant interest in addressing long-standing questions concerning the function of Skd3 and how metazoans handle mitochondrial aggregation in the absence of Hsp110 and Hsp78. This said, the study falls short on demonstrating true disaggregation activity in vitro and in vivo, behaviors that ideally would need to be validated before publication is warranted.

We respectfully disagree with the reviewers concerning the in vitro data. We have established that Skd3 is a potent disaggregase in vitro, capable of dissolving disordered aggregates and amyloid (please see further details below). We also establish that Skd3 maintains the solubility of many mitochondrial proteins in vivo, which is highly consistent with its potent disaggregase activity defined in vitro.

> While this review was being finalized, the complexities of COVID-19 emerged. Given these recent developments, the reviewers recognize that the additional experiments they initially requested may not be possible. We would therefore ask that the authors first read the \'original\' review for a sense of the issues raised by the reviewers, and then the \'updated\' review, which follows for a revised set of requests.

We thank the reviewers for their thoughtful suggestions, which have helped us to improve the manuscript. We also appreciate the recognition of the difficulties in pursuing further experiments at this time during the pandemic. Indeed, at the time of finalizing this response (May 6^th^), it is not clear when UPenn will reopen labs (indeed Philadelphia is under stay at home orders until June 4^th^). Please find our response to both the original and updated reviews below.

> Essential revisions:
>
> 1\) The authors demonstrate that Skd3 reactivates thermally inactivated luciferase but do not show directly that Skd3 actually dissociates luciferase aggregates.

We did not use thermally inactivated luciferase; rather, we used a long-established protocol (first developed in Susan Lindquist's lab) for generating large chemically denatured, luciferase aggregates, which is a gold standard for the study of protein disaggregases (DeSantis et al., 2012; Glover and Lindquist, 1998). Thus, firefly luciferase was chemically denatured with 8M urea and then rapidly diluted 100-fold into a physiological buffer (DeSantis et al., 2012; Glover and Lindquist, 1998). This protocol yields aggregated luciferase species of predominantly ∼500-2,000kDa or greater in size and very few luciferase species smaller than \~400kDa can be detected (Glover and Lindquist, 1998). Importantly, these samples are devoid of misfolded, monomeric luciferase (Glover and Lindquist, 1998). Reactivation of luciferase in this assay is thus primarily achieved by the extraction and subsequent refolding of monomeric luciferase (M~w~\~61kDa) from large aggregated structures (∼500-2,000kDa or larger) (Glover and Lindquist, 1998). Hence, in this assay, luciferase reactivation is an accurate proxy for luciferase disaggregation. We now emphasize this point in the subsection "Skd3 couples ATP hydrolysis to protein disaggregation and reactivation".

Importantly, it has also been established that Hsp70 and Hsp40 are unable to disaggregate and reactivate luciferase found in these large aggregated structures (∼500-2,000kDa or larger), but can disaggregate and reactivate luciferase trapped in aggregated species smaller than 400kDa, albeit with a low yield (Glover and Lindquist, 1998). Indeed, only the combination of Hsp104, Hsp70, and Hsp40 can disaggregate and reactivate luciferase trapped in larger aggregates greater than ∼500kDa in size (Glover and Lindquist, 1998). Throughout our studies, we include the essential negative control of Hsp70 and Hsp40 in our luciferase disaggregation/reactivation assays. We would expect to see no reactivation of luciferase by Hsp70 and Hsp40 if luciferase is trapped in large aggregates. Indeed, because we see no reactivation of luciferase by the Hsp70 and Hsp40 control, we can be certain that (1) luciferase is predominantly trapped in large aggregated structures and (2) Skd3 or Hsp104, Hsp70, and Hsp40 disaggregate and reactivate luciferase trapped in these large aggregated structures. Thus, Skd3 or Hsp104, Hsp70, and Hsp40 activity in this assay cannot be explained by simple chaperone (i.e. inhibition of aggregation) activity or simple refolding of misfolded monomeric luciferase. Rather, reactivated luciferase was recovered by disaggregation from large aggregates. We now emphasize this point in the subsection "Skd3 couples ATP hydrolysis to protein disaggregation and reactivation".

> (The solubilization of α-synuclein in Figure 4 is insufficient to demonstrate such an activity because the experiments never start with the isolated fibrils only and no equivalent experiments are shown with luciferase).

The solubilization of a-synuclein fibrils shown in Figure 4 does in fact begin with isolated a-synuclein fibrils, which are devoid of soluble a-synuclein. That is, these samples are comprised of purely α-synuclein fibrils (assembled for 5 days at 37°C with agitation) and do not contain any soluble a-synuclein. We now clarify this point in the subsection "PARL-activated Skd3 dissolves α-synuclein fibrils". The α-synuclein fibrils were acquired from Kelvin Luk's lab (Luk et al., 2012). These α-synuclein fibrils have been characterized via electron microscopy and sedimentation assays to be large, fibrillar assemblies that drive thioflavin-S positive, Lewy body-like pathology and contingent neurodegeneration in mice (whereas monomeric α-synuclein does not) (Luk et al., 2012). Thus, they are a disease-causing entity. Furthermore, these a-synuclein fibrils react with thioflavin-T (an amyloid-diagnostic dye) in vitro and no soluble a-synuclein is present in the supernatant in the absence of ATP (no ATP buffer control) (Figure 4). Given that significantly more soluble a-synuclein was observed after Skd3 treatment compared to controls, this observation supports the conclusion that Skd3 disaggregates pre-formed α-synuclein fibrils and thus is a potent protein disaggregase.

> An in vitro test for disaggregation activity (e.g., spinning down and quantifying aggregates as a function of Skd3 activity) is necessary to validate the primary point of the manuscript.

As noted above, we have provided these data for a-synuclein (Figure 4). Thus, we quantify the amount of soluble a-synuclein in the supernatant fraction after preformed a-synuclein fibrils are treated with Skd3. Our findings establish that Skd3 is able to liberate soluble forms of a-synuclein from preformed a-synuclein fibrils. In future studies, it will be of interest to pursue sedimentation-based assays of luciferase disaggregation (although as noted above, the recovery of reactivated luciferase is an accurate proxy for disaggregation under our specific assay conditions) or disaggregation of native Skd3 substrates (e.g. HAX1) in vitro to further validate Skd3 as a potent protein disaggregase.

> 2\) Similar to (1), the authors should show that Skd3 is able to disaggregate proteins in vivo (the increased solubility of HAX1 in Figure 7 is insufficient to demonstrate such an activity because it cannot distinguish between whether Skd3 resolves aggregation or prevents aggregation from happening in the first place). One approach that might be of use is that of Janowsky et al., who showed that mitochondrial Hsp78 was to induce thermal aggregation of an imported protein in purified mitochondria and then monitor disaggregation +/- Hsp78 (von Janowsky et al., 2006). Other work by Liberek provides some alternative approaches.

The reviewers raise a good point. Our cell-based studies demonstrate the insolubility of specific substrates in the intermembrane space in the absence of Skd3. These data are highly consistent with Skd3 functioning as a protein disaggregase in vivo. However, they do not exclude the possibility that Skd3 might also function as a chaperone that prevents protein aggregation. In the text, we have been careful to discuss the effect of Skd3 on proteins in the cell as "changes in solubility" in the presence or absence of Skd3. We hope that our careful discussion sufficiently emphasizes the limitations of our experiments. Regardless, our findings establish a critical role for Skd3 in maintaining proteostasis in the mitochondrial intermembrane space.

In future studies, it will be of interest to assess Skd3 disaggregase activity in vivo using the approaches suggested by the reviewers. Indeed, experiments inspired by the work of Janowsky et al. would help to establish Skd3 disaggregase activity in vivo (Janowsky et al., 2006). Nevertheless, our findings strongly suggest that Skd3 is essential to maintain proteostasis in the mitochondrial intermembrane space and are highly consistent with Skd3 functioning as a protein disaggregase (which it can in vitro).

> 3\) The changes in mitochondrial protein solubility observed in SKD3 knockout cells could be caused by loss of SKD3 disaggregase activity on specific proteins or secondary defects in protein import or membrane integration leading to accumulation of misfolded/uninserted proteins in the IMS. The authors should address this question in the Discussion.

The reviewers raise a good point. A section has been added to the Discussion to address these alternative explanations. It is possible that the changes in protein solubility are partially due to indirect effects of Skd3 on protein import into mitochondria or via sorting of membrane-targeted cargoes. We speculate that Skd3 might also play a role in protein import into mitochondria and further propose that Skd3 may play a role in maintaining the solubility of aggregation-prone mitochondrial targeting signals and membrane proteins during import and sorting (Endo et al., 1995; Poveda-Huertes et al., 2020; Yano et al., 2003). Nonetheless, our in vitro data strongly suggest that Skd3 can function as a potent protein disaggregase, and we suggest that it is likely to function in a similar manner in vivo. Indeed, Skd3 disaggregase activity is likely essential when proteins aggregate in the intermembrane space.

> 4\) The loss of ATPase and disaggregase activity seen for the isolated NBD domain (SKD3NBD) could be explained by disassembly of SKD3 hexamers in the absence of the ankyrin domains. The authors should include information on whether these constructs form stable hexamers.

The reviewers raise an interesting point. We think it is likely that a lack of oligomerization of the isolated NBD domain contributes to the lack of ATPase activity. Previous studies highlighted in the text show that isolated NBD2 constructs of bacterial ClpB form dimers and monomers in vitro and are deficient for ATPase activity (Beinker et al., 2005). Indeed, size-exclusion traces from the purification of isolated Skd3 NBD shows what appears to be a primarily dimeric species. Further studies using SEC-MALS and DLS will be very useful in quantifying this observation. Added emphasis on this point has been made in the Results section of the text (subsection "Skd3 disaggregase activity requires the ankyrin-repeat domain and NBD").

> 5\) Figures 2C/E and 3C/E: Instead of normalized data, it is important to show the real reactivation data. Are 1% or 50% of luciferase molecules reactivatable with Skd3 in this set up?

The reviewers make a valuable point, which helps to strengthens the data presented in the manuscript. We have reanalyzed the data using a native luciferase standard curve for Figures 2C, E, 3C, E, and Figure 3---figure supplement 2D. In Figure 2C, Buffer alone had 0.04 ± 0.00% (± SEM) native luciferase activity, Hsp70 + Hsp40 reactivated 0.05 ± 0.00%, Hsp104 reactivated 0.08 ± 0.01%, Hsp104 + Hsp70 + Hsp40 reactivated 7.68 ± 0.44%, ~MPP~Skd3 reactivated 2.87 ± 0.17%, and ~MPP~Skd3 (no ATP) reactivated 0.04 ± 0.00%.

In Figure 2E, Buffer alone had 0.01 ± 0.00% native luciferase activity, Hsp70 + Hsp40 reactivated 0.02 ± 0.00%, Hsp104 reactivated 0.05 ± 0.00%, Hsp104 + Hsp70 + Hsp40 reactivated 6.71 ± 0.63%, ~MPP~Skd3 reactivated 2.45± 0.32%, ~MPP~Skd3^K387A^ reactivated 0.01 ± 0.00%, ~MPP~Skd3^E455Q^ reactivated 0.01± 0.00%, and ~MPP~Skd3^Y430A^ reactivated 0.01 ± 0.00%.

In Figure 3C, Buffer alone had 0.02 ± 0.00% native luciferase activity, Hsp70 + Hsp40 reactivated 0.03 ± 0.00%, Hsp104 reactivated 0.04 ± 0.01%, Hsp104 + Hsp70 + Hsp40 reactivated 8.58 ± 1.20%, ~MPP~Skd3 reactivated 3.10± 0.44%, ~MPP~Skd3 (no ATP) reactivated 0.02 ± 0.00%, ~PARL~Skd3 reactivated 44.06± 3.78%, and ~PARL~Skd3 (no ATP) reactivated 0.08 ± 0.01%.

In Figure 3E, Buffer alone had 0.02 ± 0.00% native luciferase activity, Hsp70 + Hsp40 reactivated 0.03 ± 0.00%, Hsp104 reactivated 0.08 ± 0.00%, Hsp104 + Hsp70 + Hsp40 reactivated 16.10 ± 1.66%, ~PARL~Skd3 reactivated 38.92± 3.70%, ~PARL~Skd3^K387A^ reactivated 0.02 ± 0.00%, ~PARL~Skd3^E455Q^ reactivated 0.05± 0.02%, and ~PARL~Skd3^Y430A^ reactivated 0.05 ± 0.00%.

To determine how much luciferase could be recovered using higher concentrations of ~PARL~Skd3, we re-analyzed the data from Figure 3---figure supplement 2D. In Figure 3---figure supplement 2D, we found that 1.5µM ~PARL~Skd3 was able to reactivate 75.60 ± 8.56% native luciferase and 3.0µM ~PARL~Skd3 was able to reactivate 75.83 ± 6.80%. This information has been added to the text to supplement the figures and highlights the capability of Skd3 to disaggregate and reactivate luciferase. These findings also strongly suggest that Skd3 is capable of very effectively rescuing previously aggregated proteins.

> 6\) No direct evidence has been presented that the pore-loop Y430 makes direct contact with the substrate, hence it seems an overreach to claim that the conserved tyrosine binds the substrate. This statement should be qualified or better supported.

The subsection "Skd3 couples ATP hydrolysis to protein disaggregation and reactivation" has been amended to qualify the statement and does not directly imply substrate contact from the pore loops. Rather, it frames them as pore-loop contacts and states that these residues are pivotal for translocating substrate in other HCLR clade AAA+ proteins (DeSantis et al., 2012; Gates et al., 2017; Lopez et al., 2020; Martin et al., 2008; Rizo et al., 2019). This issue has been corrected in the Results, Discussion, and legend for Figures 2 and 3.

> 7\) Some additional mutants should be tested before concluding that disaggregase activity correlates with disease severity (a term that needs to be defined). Otherwise, this claim should be toned down.

The subsection "MGCA7-linked Skd3 variants display diminished disaggregase activity" has been modified with a short summary of the scoring system from the literature that defines the clinical severity of the disease (Pronicka et al., 2017). The experiments to test more 3-methylglutaconic aciduria, type VII (MGCA7)-linked variants were in progress. Unfortunately, due to COVID-19 they are now on hold. It will also be valuable in future studies to determine the effect of other MGCA7-linked mutations on Skd3 activity, both in vitro and in cells. Nonetheless, we have assessed the disaggregase and ATPase activity of four MGCA7-linked Skd3 variants and find that disaggregase activity is a better predictor of disease severity than ATPase activity.

> Updated Essential revisions in light of COVID-19:
>
> 1\) Please address as many points as possible raised in the original summary.

Please see above.

> 2\) Regarding Essential revision \#1, above -- the in vitro data can be strengthened by improved data analysis and discussion of the limitations, which should be possible without additional experiments. Specifically, the amount of luciferase as a % of total activity prior to aggregation should be reported to help support the idea that Skd3 is a robust disaggregase. Please also comment on the estimated fraction of α-synuclein present in fibrils in at the start of the in vitro disaggregation assay.

We discuss the controls and validation of the luciferase assays in Essential revision \#1, which demonstrate that this assay accurately reports on disaggregase activity. In Essential revision \#5, we quantify luciferase reactivation as % native luciferase activity and have added this information to supplement the figures in the text of the manuscript. We briefly summarize the analysis here: ~MPP~Skd3 can recover \~3% native luciferase activity from the aggregates, ~PARL~Skd3 can recover \~44% native luciferase activity from the aggregates and remarkably at higher concentrations, can recover \~75% native activity, which further supports the evidence of Skd3 possessing robust protein-disaggregase activity.

As noted in Essential revision \#1, the α-synuclein fibrils are devoid of soluble a-synuclein. Indeed, there is negligible monomeric α-synuclein present and the sample is virtually 100% fibrillar α-synuclein. For example, there is virtually no signal in the supernatant in the no ATP buffer control (Figure 4).

> 3\) Regarding Essential revision \#2, above -- the fact that the in vivo experiments in Figure 7 do not distinguish between disaggregation and maintaining protein solubility should be directly addressed in the Discussion.

This topic has been addressed above under Essential revision \#2 and corrected in the text.
